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Abstract
Influenza viruses cause millions of infections worldwide each year. Influenza viruses constantly acquire
mutations in their surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), through a process
called antigenic drift. HA is the main target of anti-influenza neutralizing antibodies (Abs). Due to
antigenic drift, the seasonal influenza vaccines must be updated annually to include the most
antigenically relevant strains. Each year, the World Health Organization collects thousands of clinical
influenza isolates, propagates them in cell culture, and performs both sequencing and serological
analyses to assess the antigenic characteristics of circulating viral strains. In this dissertation, we
investigate multiple factors associated with surveillance and vaccine strain selection that could be
improved to produce more reliable and effective seasonal influenza vaccines. We first demonstrate that
recent H3N2 subtype viral isolates rapidly acquire mutations in both HA and NA when propagated in cell
culture, resulting in increased receptor binding avidity or NA-dependent receptor binding, respectively.
These mutations impact antigenic analyses that are routinely used for viral surveillance. We then explore
how a single mutation in HA antigenic site B contributed to the antigenic drift and subsequent vaccine
mismatch of newly emerged H3N2 viruses during the 2014-2015 influenza season. Finally, we found that
antisera collected from previously na�ve ferrets infected for the first time with influenza (that are
commonly used for antigenic analyses during vaccine selection) do not accurately represent the Ab
repertoires found in humans that have been infected or vaccinated multiple times with different influenza
virus strains. We identified some individuals who have an Ab response targeted to a region of the HA of
H1N1 viruses that recently acquired a mutation. Overall, our studies identify ways to improve the process
of choosing seasonal influenza virus vaccine strains. We propose that the implementation of “sequencefirst” surveillance, new cell culture systems, and the use of clinical human antisera for antigenic
characterization of viruses will improve the process of selecting seasonal influenza vaccine strains.
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ABSTRACT

VACCINE STRAIN SELECTION FOR INFLUENZA A VIRUSES IS COMPLICATED BY
UNIQUE PRE-EXPOSURE HISTORIES AND RAPID MUTATION OF GLYCOPROTEINS
Benjamin S. Chambers
Scott E. Hensley
Influenza viruses cause millions of infections worldwide each year. Influenza viruses constantly
acquire mutations in their surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA),
through a process called antigenic drift. HA is the main target of anti-influenza neutralizing
antibodies (Abs). Due to antigenic drift, the seasonal influenza vaccines must be updated annually
to include the most antigenically relevant strains. Each year, the World Health Organization
collects thousands of clinical influenza isolates, propagates them in cell culture, and performs
both sequencing and serological analyses to assess the antigenic characteristics of circulating viral
strains. In this dissertation, we investigate multiple factors associated with surveillance and
vaccine strain selection that could be improved to produce more reliable and effective seasonal
influenza vaccines. We first demonstrate that recent H3N2 subtype viral isolates rapidly acquire
mutations in both HA and NA when propagated in cell culture, resulting in increased receptor
binding avidity or NA-dependent receptor binding, respectively. These mutations impact
antigenic analyses that are routinely used for viral surveillance. We then explore how a single
mutation in HA antigenic site B contributed to the antigenic drift and subsequent vaccine
mismatch of newly emerged H3N2 viruses during the 2014-2015 influenza season. Finally, we
find that antisera collected from previously naïve ferrets infected for the first time with influenza
(that are commonly used for antigenic analyses during vaccine selection) do not accurately
represent the Ab repertoires found in humans that have been infected or vaccinated multiple times
with different influenza virus strains. We identified some individuals who have an Ab response
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targeted to a region of the HA of H1N1 viruses that recently acquired a mutation. Overall, our
studies identify ways to improve the process of choosing seasonal influenza virus vaccine strains.
We propose that the implementation of “sequence-first” surveillance, new cell culture systems,
and the use of clinical human antisera for antigenic characterization of viruses will improve the
process of selecting seasonal influenza vaccine strains.
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CHAPTER 1: INTRODUCTION

Influenza Virus: The Basics
Influenza virus was first isolated and characterized by Wilson Smith, Sir
Christopher Andrewes, and Sir Patrick Laidlaw at the National Institute for Medical
Research in London in 1933 (Smith et al., 1933). Since that day, much research has been
carried out to better understand the importance of influenza virus in the human
population. A member of the Orthomyxoviridae family, three main genera of influenza
viruses have been discovered, isolated, and characterized. Influenza A viruses, which my
work focuses on, circulate most widely and cause the most severe disease in humans
(Taubenberger and Morens, 2008). Influenza B viruses only infect mammals and cause
less severe infections (Guan et al., 2011). And a lineage of influenza C viruses that
mostly infects pigs has also been discovered (Guo et al., 1983). The natural reservoir of
influenza A virus is aquatic birds or waterfowl, such as ducks and geese (Hinshaw et al.,
1980). However, it is able to infect a wide array of species including pigs, horses, whales,
bats, dogs, and of course, humans (Webster et al., 1992).
Influenza viruses cause millions of infections and thousands of deaths in the
United States each year (Kostova et al., 2013; Reed et al., 2015). During 2013 alone,
influenza infections resulted in an estimated 57,000 deaths in the United States (Xu et al.,
2016). The secret behind influenza’s ability to remain such a large public health threat on
an annual basis is its ability to adapt and mutate to escape detection by prior immunity in
the population. Influenza viruses possess a negative-sense single-stranded RNA genome
with eight separate gene segments that encode at least 15 proteins (Muramoto et al.,
1	
  

2013). The viral capsid consists of matrix protein 1 (M1) and matrix protein 2 (M2)
(Lamb et al., 1981). There are two glycoproteins, hemagglutinin (HA) and neuraminidase
(NA), present on the surface of the virion that are used for attachment and release,
respectively (Gamblin and Skehel, 2010). Nonstuctural protein 1 (NS1) is an immune
system antagonist with multiple functions (Fernandez-Sesma et al., 2006), and nuclear
export protein (NEP) is used primarily for nuclear export of replication products (O'Neill
et al., 1998). Within the virion, influenza carries its own RNA-dependent RNA
polymerase that consists of polymerase basic protein 1 (PB1), polymerase basic protein 2
(PB2), and polymerase acidic protein (PA). The polymerase forms a complex with the
viral RNA genome and nucleoprotein (NP), called the viral ribonucleoprotein (vRNP)
particle, which is essential for replication (Biswas et al., 1998). The RNA-dependent
RNA polymerase encoded by influenza lacks proofreading and introduces an average of
one mutation in each replicated genome (Drake, 1993). The introduction of point
mutations by the polymerase and the rearrangement of gene segments between different
influenza strains leads to the high adaptive ability of influenza viruses.

The Immune Response Against Influenza A Virus
During a human infection, influenza virus mainly replicates within the epithelial
cells of the host’s upper respiratory tract. The first line of defense for the host is the
innate immune response. Like in many other viral infections, the innate immune response
is key in fighting off severe influenza infections. Influenza virus is recognized by
multiple pattern recognition receptors: Toll-like receptors (TLRs) recognize dsRNA and
ssRNA (Finberg et al., 2007), retinoic acid-inducible gene I (RIG-I) recognizes the 5’2	
  

triphosphate of viral RNA (Kato et al., 2006), and NOD-, LRR-, and pyrin domaincontaining 3 (NLRP3) detects cellular damage due to influenza replication (Allen et al.,
2009). Type I interferons (IFNs) are produced and IFN-stimulated genes (ISGs) are
activated to limit influenza replication. A few of the key ISGs include MX proteins, IFNinducible transmembrane (IFITM) proteins, and ribonuclease L (RNase L). MX proteins
expressed in humans have potent anti-influenza virus activity by blocking assembly of
functional vRNPs (Verhelst et al., 2012). IFITM3 is a transmembrane host protein that
limits influenza entry into the cytosol and IFITM3-deficient mice are highly susceptible
to influenza infection (Bailey et al., 2012; Feeley et al., 2011). RNase L works in
conjunction with 2’-5’-oligoadenylate synthase (OAS) to bind and degrade viral and
cellular ssRNAs (Wreschner et al., 1981), and RNaseL-deficient mice are more
susceptible to influenza infection (Zhou et al., 2013). The innate immune response is so
effective that the influenza virus encodes its own protein, NS1, which is responsible for
antagonizing and inhibiting the innate immune response. NS1 has been shown to bind
and sequester dsRNA away from OAS so that RNase L remains inactive (Min and Krug,
2006). NS1 also interacts with TRIM25 to inhibit ubiquitination of RIG-I, and thus
prevent RIG-I signal transduction (Gack et al., 2009). NS1 plays multiple other roles in
evading host cell detection and limiting the innate immune response.
Early during infection, professional antigen-presenting cells (APCs), such as
dendritic cells and macrophages, take up and process influenza virus antigen. This
antigen can come from whole virus, from replication intermediates, or from influenzainfected cells taken up by phagocytosis (Mintern and Villadangos, 2015). The influenza
antigens are then presented on the surface of the APCs in association with major3	
  

histocompatibility complexes (MHCs) I or II, to activate both CD8+ and CD4+ T cells
(Alam and Sant, 2011; Turner et al., 2013). Mature B cells expressing a B cell receptor
(BCR) on their surface are also activated by recognizing viral antigen, and experience
proliferation through CD4+ T cell-mediated help in the germinal centers (Victora and
Nussenzweig, 2012). B cells activated early after infection produce IgM antibodies (Abs).
Activated B cells then undergo class-switching and begin producing IgG Abs that are
capable of neutralizing influenza virus in multiple ways, including binding to HA and
blocking receptor binding, inhibiting membrane fusion, or initiating Ab-dependent cellmediated cytotoxicity (ADCC) (Jegaskanda et al., 2013). Some B cells in the mucosal
tissues produce high levels of IgA instead, in order to prevent further infection of
mucosal surfaces, especially in the nasal passage (Renegar et al., 2004). Two to four
weeks after primary infection, Ab production is at its peak (Clements and Murphy, 1986).
During the primary response, a long-lived memory B cell pool is established (Buchner et
al., 1977; Skountzou et al., 2014). This memory B cell pool produces Abs specific for the
influenza strain causing the primary infection, and these cells can be recalled following
subsequent influenza virus exposures with antigenically similar strains.
Following a secondary infection with influenza, the memory B cell pool provides
a rapid production of influenza-specific Abs that reach their peak production much earlier
than in the primary response. However, in order to be reactivated, the memory B cell
must be specific for an epitope that is conserved between the previous infecting strain and
the current infecting strain. Once triggered, the B cell proliferates and undergoes somatic
hypermutation in order to generate Abs with higher affinity and increased neutralization
against the influenza antigen (Eisen, 2014). Once again, a new pool of memory B cells is
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established during this secondary response. Throughout a lifetime, humans are infected
and/or vaccinated multiple times with antigenically distinct influenza viruses. During
each subsequent exposure, a memory B cell response is recalled and further shaped
through somatic hypermutation.

Genetic Reassortment and Antigenic Shift
The main targets of anti-influenza neutralizing Abs are the two surface
glycoproteins, HA and NA. One mechanism employed by influenza viruses to escape B
cell memory and the anti-HA/NA Ab response is to swap gene segments with other
strains of influenza virus. Gene segments can be swapped between two different
influenza virus strains during co-infection of the same cell. This process is called
reassortment, and different combinations of the eight influenza gene segments can result
in the emergence of new influenza subtypes or new influenza strains with altered host
specificity and increased virulence (Steel and Lowen, 2014). The subtype of each virus is
defined by the antigenic properties of their HA and NA glycoproteins. Currently, there
are 18 known HA subtypes and 11 known NA subtypes (Tong et al., 2013). Over the past
century, several different subtypes of influenza A virus have circulated in the human
population (Fig. 1). Reassortment that results in the emergence of a new viral subtype
with antigenically novel HAs and NAs is called antigenic shift (Nelson and Holmes,
2007).
Antigenic shift occurs every time a new pandemic emerges in the human
population (Fig. 1). The pandemic of 1918 that claimed an estimated 50 million lives has
been attributed to the emergence of an H1N1 influenza A virus (Johnson and Mueller,
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2002; Taubenberger et al., 1997). These H1N1 viruses continued circulating in the human
population until 1957, when a new subtype (H2N2) emerged following the reassortment
of the circulating human H1N1 viruses with the PB1, HA, and NA genes of an avian
H2N2 virus (Schafer et al., 1993). The “Asian Flu” of 1957 was a milder pandemic but
still claimed 70,000 lives in the United States (Noble, 1982). Another antigenic shift
event occurred in 1968 when the H3N2 “Hong Kong Flu” pandemic emerged and killed
34,000 people in the United States (Noble, 1982). In this case, the prior H2N2 viruses
acquired the HA and PB1 genes from an avian H3N2 virus (Gething et al., 1980).
Antigenically drifted H3N2 viruses from this pandemic are still circulating today. In
1977, H1N1 viruses returned to circulation, likely following a lab containment accident
that reintroduced H1N1 viruses into a partially naïve population (Kendal et al., 1978;
Webster et al., 1992). These H1N1 viruses were genetically similar to those that had
circulated in the early 1950s (Nakajima et al., 1978; Scholtissek et al., 1978). Older
adults had prior immunity from exposure to similar strains, and therefore the majority of
disease burden occurred in children and young adults under the age of 25 (Kilbourne,
2006). These H1N1 viruses are now referred to as the seasonal H1N1 (sH1N1) viruses as
a way to separate them from the antigenically distinct pandemic (pH1N1) viruses that
emerged in 2009.
The “Swine Flu” of 2009 resulted in many severe infections, surprisingly only 5%
of them being in adults over the age of 51 (Dawood et al., 2009). Elderly individuals
were thought to be protected due to similarities in the HA between the pH1N1 viruses of
2009 and the H1N1 viruses that circulated prior to the 1950s (Skountzou et al., 2010). As
discussed earlier in this chapter, memory B cells primed early in life can be recalled when
6	
  

confronted with new strains that possess B cell epitopes conserved in older viral strains.
The pH1N1 viruses were the result of a quadruple reassortment between gene segments
from human H3N2 viruses, classical swine viruses, Eurasian swine viruses, and a North
American avian virus introduced through a swine lineage (Garten et al., 2009).
Approximately 20-30% of the amino acid residues in HA are different between pH1N1
viruses and sH1N1 viruses (Li et al., 2012). The sH1N1 viruses quickly became extinct
following the emergence of pH1N1 viruses, possibly because pH1N1 viruses had higher
fitness (Perez et al., 2009) or because pH1N1 viruses elicited cross-reactive stalk Abs and
anti-NA Abs that bound with high affinity and completely neutralized the sH1N1 viruses
(Palese and Wang, 2011). Currently, both pH1N1 and H3N2 influenza A viruses are
actively circulating in the human population on an annual basis and both will be
discussed further in this dissertation.

Antigenic Importance of Hemagglutinin and Antigenic Drift
As stated previously, there are two glycoproteins exposed on the surface of
influenza viruses. The surface is covered in a 10:1 ratio of HA to NA (Mitnaul et al.,
1996). NA is a tetramer that is mainly responsible for the release of newly formed virions
from the surface of host cells. HA exists as a trimer on the virion surface and is
responsible for binding to the target cell via its receptor, a terminal sialic acid residue on
the surface of the host cell. HA is synthesized as a precursor, called HA0, which must be
cleaved by a trypsin-like protease to form the activated confirmation of HA1 and HA2
(Gething et al., 1986). After binding to the sialic acid receptor through HA1, the virus is
taken into the cell through dynamin-dependent, clathrin-mediated endocytosis (Patterson
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et al., 1979). A decrease in pH within the endosome triggers a conformational change that
exposes the fusion peptide within HA2 (Skehel et al., 1982). The fusion peptide then
imbeds into the host endosomal membrane and forms a pore for release of the vRNPs
into the cytoplasm (Stegmann et al., 1991). Abs that bind to HA can neutralize the virus
in multiple ways, including prevention of HA0 cleavage, obstruction of receptor binding,
and inhibition of membrane fusion (Brandenburg et al., 2013).
Previous work completed in the 1970s and 1980s mapped the immunodominant
epitopes on HA where most anti-influenza neutralizing Abs bind. These
immunodominant epitopes are referred to as antigenic sites. Escape mutants were
generated in the presence of monoclonal Abs to identify the four antigenic sites (Sa, Sb,
Ca, and Cb) of H1N1 viruses (Caton et al., 1982). Sequence data and the interpretation of
past antigenic drift mutations were studied to identify the five antigenic sites (A, B, C, D,
and E) of H3N2 viruses (Wiley et al., 1981). The antigenic sites are located across the
head of the HA trimer (Fig. 2). This region is the most exposed and thus the most
accessible for binding of Abs. Neutralizing Abs that bind the more conserved stalk
domain located closer to the membrane have also been identified (Corti et al., 2011;
Ekiert et al., 2009; Okuno et al., 1993; Sangster et al., 2013; Sui et al., 2009), but the vast
majority of anti-influenza neutralizing Abs bind to the easily accessible globular head
domain of HA. It is also important to note that not all neutralizing Abs bind to one of
these classic antigenic sites. The classic antigenic sites can be thought of as defining a
general location on the HA trimer, rather than identifying a very specific set of individual
residues that are involved in Ab binding.
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Because most neutralizing Abs bind to these antigenic sites, they are also the most
common sites for the accumulation of antigenic drift mutations. Genetic drift is defined
as the continuous accumulation of nonsynonymous mutations in viral gene segments; a
result of the RNA-dependent RNA polymerase that lacks proofreading (Nelson and
Holmes, 2007). Antigenic drift occurs when immune pressure leads to the fixation of
those mutations that abrogate the binding of neutralizing Abs (Fitch et al., 1997).
Throughout the evolution of H3N2 influenza viruses between 1968 and 2003, over 70
mutations became fixed in the H3N2 HA; 94% of which were in the classic H3N2
antigenic sites identified previously (Smith et al., 2004; Wiley et al., 1981). A recent
transposon mutagenesis screen concluded that HA, the globular head domain in
particular, is the most permissible region to mutations in the influenza genome (Heaton et
al., 2013). Viral mutations can also alter viral fitness through mechanisms that do not
involve abrogating Ab binding. For example, mutations throughout the influenza
genome can change receptor specificity (Zhang et al., 2013a), alter neuramindase activity
(Richard et al., 2008), switch host tropism (Mehle et al., 2012), increase polymerase
activity (Liu et al., 2016), and promote nuclear import of vRNP particles (Sediri et al.,
2015).
It is important to understand how mutations in HA can lead to changes in host
tropism. Influenza viruses attach to cells by binding to sialic acid receptors. Sialic acid is
linked to galactose through either an α2,3 or an α2,6 linkage. Most avian influenza
viruses are specific for α2,3-linked sialic acids while most human influenza viruses are
specific for α2,6-linked sialic acids (Rogers et al., 1983). Mutations in HA can alter sialic
acid specificity and allow viruses to jump from one species to the other (Tharakaraman et
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al., 2013). This scope of specificity makes sense when considered in the context of which
sialic acids coat the cells in certain species. In aquatic birds, their guts (the main site of
influenza virus replication in birds) are coated with predominantly α2,3-linked sialic
acids (Pillai and Lee, 2010). However, the human upper respiratory tract (where
influenza mainly replicates in humans) is mostly coated in α2,6-linked sialic acids
(Shinya et al., 2006; Thompson et al., 2006). Interestingly, the human lower respiratory
tract does contain α2,3-linked sialic acids, which may help to explain why avian-derived
influenza viruses like H5N1 and H7N9 often spread lower into the lungs and cause
pneumonia and death in human infections (Knepper et al., 2013; Zeng et al., 2013). The
gut of swine contains a mixture of both α2,3- and α2,6-linked sialic acids, explaining why
they can act as so-called “mixing vessels” for influenza reassortment of multiple types of
strains (Trebbien et al., 2011). Other than switching host tropism, mutations in the HA
receptor binding domain can simply increase or decrease receptor binding avidity (Lin et
al., 2012). In fact, many mutations in HA that alter antigenicity also increase or decrease
receptor binding avidity (Hensley et al., 2009). This leads to complications during
antigenic analyses of recently emerged mutant viruses.

Original Antigenic Sin
Over 50 years ago, Thomas Francis, Jr. coined the term “original antigenic sin” as
a way to describe the observation that even when infected with a novel influenza strain,
humans will produce Abs against previously encountered strains at the expense of
mounting effective responses against the current novel strain (Davenport et al., 1953;
Francis, 1960). Ever since then, original antigenic sin (OAS) has been explored more in
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depth to better establish the role it plays in secondary immune responses against
influenza virus. Various studies have focused on antigenic seniority and the role of OAS
in H3N2 responses (Lessler et al., 2012), longitudinal analyses of H1N1, H2N2, and
H3N2 responses (Miller et al., 2013), and Ab responses against the 2009 pH1N1 virus
(Wrammert et al., 2011). OAS following influenza infection has been observed in
multiple other animal models including rabbits (Fazekas de St and Webster, 1966b), mice
(Virelizier et al., 1974b), and ferrets (Webster, 1966). Apart from other animal models,
OAS has also been detected in other pathogens. For example, OAS has been observed
following sequential dengue virus infections and may play a role in shaping the Ab
response against human immunodeficiency virus (HIV) over time (Ciupe et al., 2011;
Halstead et al., 1983).
Mechanisms that lead to OAS are not completely understood, but OAS likely
occurs when cross-reactive B cell clones are recalled from the memory pool during
infections with antigenically related influenza strains (Li et al., 2013b; Wrammert et al.,
2011). The cross-reactive OAS Abs these memory B cells produce quickly eliminate the
new antigen before any novel Ab responses can be established (Kim et al., 2009). OAS
has been hypothesized to lead to reduced vaccine efficacy. However, recent studies have
shown that OAS Abs that bind with low affinity can afford protection against secondary
viral challenges (Linderman and Hensley, 2016). Recent studies have also explored how
the effects of OAS can be avoided during vaccination. Repeated vaccination with the
same novel strain or the use of adjuvants potentially limits OAS (Kim et al., 2012). The
impact of OAS on the secondary immune response against influenza virus will be
explored in Chapter 4.
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Current Vaccination Methods
The best approach for limiting influenza infection in the human population is
annual vaccinations with currently circulating influenza strains. Jonas Salk and Thomas
Francis, Jr. developed the first influenza vaccine in 1938 by using ultraviolet radiation to
inactivate the virus (Salk et al., 1940). Today, the most common approach is still to
vaccinate with an inactivated virus; specifically, an inactivated split virus or subunit
vaccine that is grown in eggs (Wong and Webby, 2013). These inactivated vaccines
contain an H1N1 influenza A virus component, an H3N2 influenza A virus component,
and one or two influenza B components. They are called trivalent inactivated vaccines
(TIVs) or quadrivalent inactivated vaccines (QIVs) depending on how many influenza B
strains they include, and they are injected into the muscle of recipients. Inactivated
vaccines have been used for over 70 years and have a good history of reducing disease in
the human population (Hannoun, 2013). During a typical season, the inactivated vaccines
have an efficacy of 60-70% (Treanor et al., 2012). Over the past couple decades, the
recommendation for vaccination in the United States has expanded to include the entire
population. Previously, influenza vaccination was focused primarily on at-risk groups
including healthcare workers, pregnant women, young children (<6 years old), and the
elderly (>65 years old) (Hannoun, 2013). However, as the public health impact and
severity of influenza virus has increased and become better understood, the United States
began recommending in 2010 that everyone over the age of 6 months be vaccinated
against influenza virus on an annual basis (Fiore et al., 2010).
Another current method of influenza vaccination is the use of attenuated viruses.
For example, FluMist is a licensed vaccine that contains a whole virus that can only grow
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at lower temperatures (25°C). It is injected into the nose of the recipient where it can
replicate and elicit an immune response. However, the vaccine strain is unable to expand
into the lungs and cause an infection because it cannot replicate at the internal body
temperature of 37°C. The live-attenuated influenza vaccines (LAIVs) do present a couple
advantages over the inactivated subunit vaccine. First, LAIVs replicate in the nasal cavity
and thus elicit T-cell responses that are an important part of influenza immunity (Mohn et
al., 2015). Second, LAIVs also elicit robust mucosal IgA Ab responses (Ambrose et al.,
2012) compared to the inactivated subunit vaccines which elicit primarily IgG-dominated
Ab responses (Cox et al., 1994). Although early uses of the LAIVs were successful,
recent formulations of FluMist in particular have elicited very poor responses and have
resulted in very low vaccine efficacies. For example, the LAIV vaccine efficacy was
reported at only 3% during the 2015-2016 season (Anonymous, 2016). This has led to the
recent recommendation by the CDC to only use inactivated subunit vaccines during the
upcoming 2016-2017 influenza season (Anonymous, 2016).
The future of influenza vaccination is targeted at generating more cross-reactive
vaccine responses, or even a universal vaccine that will elicit lifelong influenza
immunity. One approach currently being explored is the use of peptide antigens that
contain epitopes commonly recognized by B cell or T cell responses. For example, an NP
epitope encased in a liposome has been shown to elicit potent T cell responses and reduce
viral lung titers in influenza-infected mice (Ninomiya et al., 2002). A second approach
being pursued is recombinant proteins. Headless HA proteins expressed on virus-like
particles (VLPs) or on nanoparticles have shown promise in mice and ferrets by
increasing the cross-reactivity of the anti-influenza Ab response by targeting it towards
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the more conserved stalk domain of HA (Steel et al., 2010; Yassine et al., 2015). Another
version of recombinant proteins being employed to elicit stalk-focused Abs is chimeric
HA proteins. By sequentially vaccinating with recombinant proteins that all share the
same HA stalk but contain different HA globular heads, the recalled Ab response is
focused against the conserved stalk domain (Krammer et al., 2014; Krammer and Palese,
2013). These along with many other approaches (such as M2-focused Abs, adjuvants, and
DNA-based vaccines) could end up being the future of influenza vaccination. But in the
mean time, it is important to continue improving the current method of vaccination, strain
selection, and vaccine manufacturing.

Influenza Virus Surveillance and Vaccine Strain Selection
Currently, the influenza vaccine must be updated each year to possess the most
relevant strains of H1N1, H3N2, and influenza B viruses. The constant accumulation of
mutations in HA via antigenic drift can make vaccine selection a very difficult process. In
order to select the best possible vaccine strains on an annual basis, the World Health
Organization (WHO) and Centers for Disease Control and Prevention (CDC) employ
constant surveillance (Stöhr et al., 2012). Throughout the year, thousands of influenza
isolates are collected from infected individuals. These strains are grown in cell culture or
eggs to obtain a workable stock, antigenically characterized, and sequenced (Krauss et
al., 2012; Stöhr et al., 2012). When antigenically distinct viruses are detected, the vaccine
is updated. The most common method employed for determining antigenic differences
compared to the current vaccine strain is the serological assay called the
hemagglutination inhibition (HAI) assay (Stöhr et al., 2012). The HAI assay measures the
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amount of antisera required to inhibit a virus from binding to its sialic acid receptor. The
WHO and CDC mainly use antisera collected from previously naïve ferrets infected for
the first time with the current influenza vaccine strain (Stöhr et al., 2012). This “primary
ferret antisera” is then used in HAI assays and in in vitro neutralization assays to detect
when circulating strains escape detection by the Abs elicited by the current vaccine strain.
The in vitro neutralization assay is another serological assay and it measures the ability of
antisera to neutralize the growth of virus in cell culture. It is a more reliable assay in
identifying all functionally active Abs that neutralize virus, compared to the HAI assay
which can only detect Abs that block virus-sialic acid interactions (Bachmann et al.,
1999; Zhu et al., 2011). For example, there are HA stalk-binding Abs that are HAInegative (do not affect binding) but still neutralize virus by blocking membrane fusion or
inhibiting proteolytic cleavage of HA0 (Pica et al., 2012). Therefore, HAI assays and in
vitro neutralization assays using mainly sera collected from previously naïve ferrets are
used to characterize the antigenic properties of newly emerged viruses.
However, multiple factors can complicate the vaccine selection process. For
example, one caveat is that the vaccine strains need to be chosen over nine months before
the actual influenza season begins in order to manufacture enough vaccine doses. This
means that between the time that the vaccine composition is selected and the time it is
actually given to humans, the circulating viruses could acquire additional mutations and
establish an HA identity that is undetectable by the vaccine-elicited Ab response. Every
few years, antigenic drift that occurs leading up to an influenza season results in a
vaccine mismatch where vaccine efficacy is drastically reduced (Carrat and Flahault,
2007; Chambers et al., 2015; Xie et al., 2015). Another complicating factor is that there
15	
  

are no established definitions for how much antigenic change is required before a vaccine
update is called for. The HAI and in vitro neutralization assays can quantify the
difference in ability of antisera to bind and neutralize different viruses. However, there is
no set amount of antigenic change that triggers an automatic vaccine update. The choice
to update the vaccine is left up to the consideration and conclusions of the WHO and
CDC. In general, the H3N2 and influenza B components of the vaccine have been
updated every 2-4 years on average (Fouchier and Smith, 2010; Smith et al., 2004).
However, the current H1N1 vaccine strain has not been updated since 2009, when the
pH1N1 viruses first emerged. The last major complication is that sera collected from
previously naïve ferrets infected with influenza virus a single time are used to represent
human immunity. Although ferrets are a great model of influenza infection and
immunity, recent studies have challenged whether ferret antisera following a single
infection can truly represent the spectrum of Ab response specificities found in the
human population (Fonville et al., 2016; Li et al., 2013b).

Ferrets and Mice as Models for Influenza Infection
Two of the most commonly used animal models for influenza virus infection and
immunity are mice and ferrets. The effective use of mice (Shope, 1935) and ferrets
(Shope, 1934) in influenza research was established immediately after the first isolation
of influenza virus in 1933. As mice and ferrets will both be employed in the chapters that
follow, it is important to establish both the pros and cons associated with both systems so
that data can be accurately interpreted. Mice are a reliable, genetically stable, less
expensive, and easily manipulated system used to study influenza virus infections. Mice
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become infected when challenged with a sufficient dose of influenza virus and show
multiple signs of illness. Weight loss, lethargy, and ruffled fur are all indications of
infection severity and have been used as reliable measurements in many early vaccine
and antiviral efficacy studies (Gubareva et al., 1998; Tumpey et al., 2002). Passive Ab
transfer experiments that measure the ability of Abs to prevent severe infection are also
commonly carried out in mice (Francis and Magill, 1935; Renegar and Small, 1991).
However, using mice as a model for influenza research does present multiple drawbacks.
Influenza strains often acquire mutations and become adapted to replicate well in mice
(Keleta et al., 2008). For example, one of the most commonly used influenza lab strains,
A/Puerto Rico/08/1934 (PR8), is a heavily mouse-adapted strain (Gerber et al., 1955).
Comparisons between mouse-adapted and human-adapted strains cannot always be made
with certainty due to adaptive mutations that have arisen in the virus when passaged in
mice. A second main concern with mice is that their presentation of illness does not
match the human response to an influenza infection. Mice do lose weight, but do not
develop a fever during infection (Dybing et al., 2000). Viral replication and tissue
damage is concentrated in the lower respiratory tract in mice, instead of the upper
respiratory tract like it is in humans (Belser et al., 2010). Transmission studies with
H1N1, H3N2, and H5N1 viruses have also proven unsuccessful in mice (Lowen et al.,
2006). Overall, mice are a good model for answering some experimental questions but
cannot provide a true representation of human influenza infection.
All the limitations of the mouse model actually represent the strengths of the
ferret model. Ferrets are easily infected with non-adapted human influenza viruses and
pathogenesis presents in very similar ways compared to human infections (Herlocher et
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al., 2001). For example, ferrets infected with influenza virus experience respiratory
distress, fever, nasal discharge, anorexia, and lethargy similar to humans (Smith et al.,
1933). Developing classic clinical symptoms makes ferrets great models for testing
antiviral efficacy (Govorkova et al., 2007; von Itzstein et al., 1993). Another major
advantage to using ferrets is that they can transmit influenza virus via aerosols. Aerosol
transmission is the major method of transmission in human influenza outbreaks. Many
successful transmission studies have been conducted using the ferret model, including
transmission of H7N2 (Belser et al., 2008), H9N2 (Wan et al., 2008), and the recent
swine-origin pH1N1 of 2009 (Munster et al., 2009). The major downside to using the
ferret model for influenza research is that they are expensive and require specialized
animal facilities (Maher and DeStefano, 2004).
The ferret model is employed as the main animal model for virus surveillance and
vaccine selection (Belser et al., 2011). And although recent studies have concluded that
sera collected from previously naïve ferrets infected with influenza for the first time
cannot represent the entire spectrum of anti-H1N1 Ab specificities found in humans,
ferrets sequentially infected with antigenically distinct H1N1 strains do recapitulate the
unique Ab responses seen in humans (Li et al., 2013b; Linderman et al., 2014). However,
previously naïve ferrets infected with influenza a single time continue to be the main
standard used in viral surveillance and vaccine strain selection.

Main Experimental Questions
Surveillance for vaccine selection currently relies on collecting viral isolates,
growing them in cell culture and eggs, characterizing their antigenic profile using sera
18	
  

collected from previously naïve ferrets infected with influenza for the first time, and
sequencing their HA gene (Stöhr et al., 2012). However, multiple steps could be taken to
improve this process and select more effective influenza vaccine strains in the future. The
chapters below will explore the main aspects of influenza surveillance and vaccine strain
selection that need to be improved.
First, we will investigate whether antigenicity of recent H3N2 clinical isolates is
affected by cell culture propagation. Recent H3N2 influenza viruses have poor receptor
binding avidity and grow poorly in cell culture because they cannot bind well to their
sialic acid receptors for entry (Gulati et al., 2013; Lin et al., 2012; Nobusawa et al.,
2000). We find that during propagation in cell culture, H3N2 clinical isolates rapidly
acquire mutations in both HA and NA. These mutations result in increased receptor
binding avidity, NA-dependent sialic acid receptor binding, and altered antigenic
characteristics.
Second, we will explore how a single mutation in an antigenic site of HA can
contribute to a major vaccine mismatch. The H3N2 vaccine component failed during the
2014-2015 influenza season due to a mismatch between the vaccine strain and the viral
strains that actually circulated. We determined that mutations that arose in the HA
globular head were responsible for the antigenic drift that caused the vaccine mismatch.
The main contribution was from a single mutation in HA antigenic site B, a region that
has been implicated multiple times in the past for antigenic drift mutations that
contributed to the evolution of H3N2 viruses (Koel et al., 2013; Popova et al., 2012).
Third, we will examine whether recent mutations in the pH1N1 virus subtype are
being antigenically mischaracterized using sera collected from previously naïve ferrets
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infected with influenza for the first time. Humans are infected and/or vaccinated with
antigenically distinct influenza viruses multiple times throughout their lives. The Ab
responses primed early in their lives are recalled during each subsequent secondary
infection with antigenically related strains. We find that childhood sH1N1 infections
shape the specificity of Ab responses elicited against pH1N1 viruses. Specifically, the Ab
responses elicited by pH1N1 viruses are focused on epitopes conserved between the
pH1N1 viruses and the sH1N1 viruses that individuals were likely infected with early in
life. In Chapter 4, we will explore whether mutations that arise in these unique Ab
binding epitopes are being antigenically mischaracterized by the current antigenic
analyses used in surveillance that employ mainly antisera isolated from pH1N1-infected
ferrets who do not have any prior H1N1 exposures.
Together, our studies demonstrate the importance of updating current surveillance
and vaccine strain selection techniques in order to produce more effective seasonal
influenza vaccines. We propagated clinical isolates in cell culture, sequenced HA genes,
and conducted antigenic analyses with both ferret and human antisera to identify
antigenically important mutations. We conclude that recent H3N2 viruses rapidly acquire
mutations in MDCK cell culture, single mutations in HA can cause antigenic drift and
subsequent vaccine mismatches, different humans have unique anti-pH1N1 Ab responses
due to unique pre-exposure histories, and newly arisen mutations are being antigenically
mischaracterized by sera isolated from ferrets recovering from primary infections. Due to
all these concerns, multiple steps need to be taken to improve upon the current vaccine
strain selection process. The use of “sequence-first” surveillance, new cell culture
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systems, and sequentially infected ferret or clinical human antisera in antigenic analyses
would likely increase vaccine effectiveness.
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FIGURES FOR INTRODUCTION
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Figure 1. Timeline of influenza A virus circulation in the human population over the
past century.
This timeline denotes the circulation of different influenza A virus subtypes in the human
population since 1918. The emergence of a new subtype is associated with genetic
reassortment and antigenic shift. The continued circulation of a subtype is associated with
continuous antigenic drift. The seasonal H1N1 and pandemic H1N1 subtypes are
abbreviated as sH1N1 and pH1N1, respectively. The two subtypes currently circulating
on a seasonal basis, pH1N1 and H3N2, are highlighted in red.
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Figure 2
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Figure 2. Previously identified antigenic sites mapped on the H3 and H1 crystal
structures.
The classic antigenic sites for both H3N2 viruses (Wiley et al., 1981) and H1N1 viruses
(Caton et al., 1982) were originally identified in the early 1980s. Here, the five classic
antigenic (Ag) sites of H3 HA (A) and the four classic antigenic sites of H1 HA (B) are
mapped on the HA trimers (Protein Data Bank (PDB) entries 1HGG and 1RVX) in
different colors identified by the legends. The sialic acid receptor is shown in white.
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CHAPTER 2: RECENT H3N2 INFLUENZA VIRUS CLINICAL
ISOLATES RAPIDLY ACQUIRE HEMAGGLUTININ OR
NEURAMINIDASE MUTATIONS WHEN PROPAGATED FOR
ANTIGENIC ANALYSES

Parts of this chapter were previously published in:

Chambers BS, Li Y, Hodinka RL, and Hensley SE. (2014) Recent H3N2 influenza virus
clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when
propagated for antigenic analyses. J Virol 88(18):10986-10989.

SUMMARY
Influenza A viruses continuously acquire mutations in their surface glycoproteins,
hemagglutinin (HA) and neuraminidase (NA), in order to escape neutralizing immune
responses and continue circulating. Each year, influenza virus surveillance is required to
determine the most antigenically relevant strains to include in the vaccine. Thousands of
isolates are collected, expanded in cell culture, and then antigenically characterized and
sequenced. Recent H3N2 viruses have drastically decreased receptor binding avidity and
thus acquire adaptive mutations when grown in cell culture. We passaged 10 clinical
isolates in cell culture and determined that HA and NA mutations are acquired rapidly.
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These mutations result in growth to higher infectious titers and increased agglutination of
red blood cells. The NA mutations acquired during propagation led to NA-dependent
binding of the sialic acid receptor, and the HA mutation led to increased receptor binding
avidity. Both of these characteristics have profound effects on antigenic analyses, and
could be negatively affecting annual influenza vaccine surveillance.

INTRODUCTION
H3N2 influenza A viruses have circulated continuously in the human population
since 1968. In that time, they have steadily acquired mutations in the antigenic sites of
both of the glycoproteins present on their surface, hemagglutinin (HA) and
neuraminidase (NA) (Yewdell, 2011). This process of acquiring mutations to evade
neutralizing antibody (Ab) responses is called antigenic drift and has occurred in H3N2
viruses since 1968 (Smith et al., 2004). HA is the major antigenic target of the humoral
immune system, and thus acquires the majority of antigenic drift mutations (Smith et al.,
2004). Mutations in HA are able to change both antigenicity and receptor binding avidity
simultaneously (Hensley et al., 2009; Underwood et al., 1987). Recent H3N2 viruses
have dramatically reduced receptor binding avidity and altered receptor specificity
(Gulati et al., 2013; Lin et al., 2012).
Due to antigenic drift, the influenza vaccine must be updated on an annual basis
to include the most antigenically relevant strains. Surveillance is conducted continuously
to monitor which strains are circulating and when an antigenically drifted strain emerges.
Viral isolates are collected from infected individuals, expanded in cell culture to obtain a
working stock, sequenced, and then antigenically profiled using serological assays with
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sera collected from previously naïve ferrets infected with influenza for the first time
(Krauss et al., 2012; Stöhr et al., 2012). The main serological assay used to determine
antigenic change is the hemagglutination inhibition (HAI) assay. The HAI assay
measures the amount of antisera required to inhibit the agglutination of red blood cells
(RBCs) bound by virus (Hirst, 1942). HA is the sole attachment factor for the majority of
influenza virus strains, and HA agglutinates RBCs by binding to sialic acid. HAI assays
are therefore intended to quantify relative amounts of HA-specific antibodies. However,
recent studies demonstrated that some H3N2 and H1N1 strains agglutinate RBCs through
NA-sialic acid interactions (Hooper and Bloom, 2013; Lin et al., 2010; Zhu et al., 2012).
With drastically decreased receptor binding avidity, recent H3N2 viruses have
difficulty growing in cell culture or eggs and have been shown to acquire mutations in
HA and NA (Chen et al., 2010b; Nakowitsch et al., 2014; Nakowitsch et al., 2011;
Skowronski et al., 2014; Wang et al., 2013). The extent of these mutations and their
effect on antigenic analyses has not yet been investigated in depth. In this study, we
completed a series of experiments to determine whether HA and/or NA mutations
commonly arise when contemporary clinical H3N2 isolates are expanded in cell culture
and the impact they have on antigenic testing. As expected, we observed the emergence
of multiple mutations in both HA and NA after a single passage in cell culture. NA
mutations resulted in NA-dependent agglutination and an HA mutation resulted in
increased receptor binding avidity, both leading to the alteration of antigenic analyses.
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RESULTS
Expanded clinical H3N2 isolates bind cells in an NA-dependent manner
During the 2012-2013 influenza season, respiratory secretions were collected at
the Children’s Hospital of Philadelphia from 10 children (ages 1 month to 7 years old)
infected with H3N2 influenza virus. Remaining de-identified clinical samples were
passaged two times on Madin-Darby canine kidney (MDCK) cells, which are routinely
used by surveillance labs for isolating human viruses (Krauss et al., 2012). After each
passage, supernatants were collected and analyzed. Infectious titer was quantified by a
50% tissue culture infective dose (TCID50) assay and agglutination was measured using
both turkey and guinea pig RBCs.
Following two passages, 9 of 10 MDCK cultures contained infectious virus
(Table 1). However, only 5 of these isolates were able to agglutinate turkey RBCs.
Recent studies have shown that some influenza strains bind more effectively to guinea
pig RBCs than to turkey RBCs (Barr et al., 2010; Klimov et al., 2012; Nicholls et al.,
2008). When guinea pig RBCs were used for agglutination analysis, all 9 of the infectious
virus isolates presented agglutination correlated with their measured infectious titers. To
determine whether agglutination of each viral isolate was mediated by HA or NA, we
repeated agglutination analyses in the presence of 10 µM oseltamivir, a compound that
binds in the sialic acid binding site of NA (Collins et al., 2008). Adding in oseltamivir
reduced the agglutination of four isolates (Table 1). Surprisingly, only one isolate (Isolate
6) was able to agglutinate turkey RBCs through an NA-independent mechanism. Taken
together, these results indicate that 9 of the 10 isolates were able to grow in cell culture,
and that 4 of the expanded isolates bind to cells in an NA-dependent mechanism.
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Mutations emerge in HA and NA during passage in cell culture
We grouped all the viral isolates into four categories: viruses that agglutinate via
an NA-dependent mechanism (n = 4), a virus that agglutinates via an NA-independent
mechanism (n = 1), viruses that agglutinate poorly (n = 4), and a virus that was not
detected after expansion (n = 1) (Tables 1 and 2). We sequenced the HA1 and NA genes
from the primary clinical material and the MDCK-expanded virus of each isolate to
identify mutations that may explain the increase in agglutination and the NA-dependent
binding. We compared the HA1 and NA sequences to the A/Victoria/361/2011
(A/Victoria/361/11) H3N2 vaccine strain (EpiFlu accession numbers EPI349103 and
EPI349104). The primary isolates all contained multiple HA and NA sequence
differences compared to the A/Victoria/361/11 vaccine reference strain (Table 2). All
four of the viral isolates with NA-dependent agglutination acquired additional mutations
at NA residue 151 during expansion, but did not acquire any HA mutations. Previous
work in the field has already demonstrated that the two NA mutations we observe here,
D151G and D151N, enable NA-dependent viral attachment (Lin et al., 2010; Zhu et al.,
2012). Also consistent with previous sequencing studies, we did not detect these NA
mutations present at any level in the primary isolate (Lee et al., 2013).
The isolate that agglutinates through an NA-independent manner (Isolate 6) did
not acquire any mutations in NA but did acquire a single HA mutation at residue 237
during expansion (Table 2). This isolate also contained one unique mutation, HA F209S,
which was present in both the primary sample and the expanded isolate. We did not
detect any new HA or NA mutations in the five MDCK-expanded viral isolates that grew
to low titers and agglutinated RBCs poorly.
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Characterizing the P237L HA mutation
Only the isolate with NA-independent agglutination (Isolate 6) contained
mutations at HA residues 209 and 237. To determine if either of these HA mutations
(F209S or P237L) was responsible for the increased growth and agglutination of Isolate
6, we completed reverse-genetics studies by inserting F209S and P237L into both the
A/Victoria/361/11 H3N2 vaccine strain and Isolate 2. We chose Isolate 2 for reversegenetics experiments because it agglutinates poorly after expansion and did not acquire
any mutations (Tables 1 and 2). We rescued virus containing the mutated HA genes, the
NA of either A/Victoria/361/11 or Isolate 2, and the PR8 internal genes by transfecting
293T/MDCK co-cultures. Viruses containing the P237L mutation, but not the F209S
mutation, grew to high titers and agglutinated RBCs in the presence of oseltamivir,
demonstrating NA-independent binding (Table 3). HA residue 237 is located at the HA
trimer interface (Fig. 3A), and thus may contribute to increased growth and agglutination
by increasing HA stability. We determined the relative receptor binding avidities of
viruses possessing P237 or L237 by measuring agglutination using RBCs pre-treated with
receptor-destroying enzyme (RDE) that removes sialic acid receptors (Hensley et al.,
2009; Yewdell et al., 1986). The A/Victoria/361/11 virus with the P237L mutation
efficiently agglutinated RBCs treated with larger amounts of receptor-destroying enzyme
(RDE, a neuraminidase), indicating that viruses with L237 possess higher receptor
binding avidities (Fig. 3B).
Previous work has demonstrated that viruses with higher avidity are difficult to
inhibit in HAI assays and may result in artificially lower HAI titers even if antigenicity
has not changed. To test whether the P237L mutation impacts antigenic analyses, we
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conducted an HAI assay using ferret antisera generated against the A/Victoria/361/11
vaccine strain. Addition of the P237L mutation resulted in a twofold decrease in HAI
titers compared to the WT virus (Fig. 3C), consistent with the idea that increased receptor
binding avidity can alter the interpretation of antigenic analyses.
Although standard Sanger sequencing could not detect the P237L HA mutation in
the original clinical material of Isolate 6 (Table 2), low levels of the mutation were
detected in the original clinical isolate by sequencing individual clones following TA
cloning of PCR products (Fig. 3D). Out of the 21 total clones sequenced, ~5% contained
L237. This indicates that the P237L mutation at the HA trimer interface was present in a
small subset of the original clinical isolate and was able to grow out during expansion,
presumably due to increased HA stability and receptor binding avidity.

DISCUSSION
Taken together, our data indicate that recent clinical H3N2 strains replicate poorly
in MDCK cells and rapidly acquire either HA or NA mutations when propagated in vitro
prior to antigenic testing. These mutations increase viral growth and agglutination titers
and can potentially skew HAI assays. The goal of HAI assays is to detect HA antigenic
changes, and therefore it is difficult to interpret data when agglutination is mediated by
mutated NAs. The addition of oseltamivir directly into HAI assays may circumvent this
problem (Lin et al., 2010). We have previously shown that HA mutations that alter
receptor binding avidity can skew antigenic maps based on HAI assays (Li et al., 2013a),
and recent computational methods have been developed to create antigenic maps that
account for variations in viral avidity (Bedford et al., 2014; Li et al., 2013a). Future
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studies should focus on alternative cell-derived systems for propagating primary
influenza isolates, such as MDCK cells engineered to express different types of sialic
acid receptors (Krauss et al., 2012; Oh et al., 2008). Additional studies should also
address if cell culture-derived mutations in vaccine strains impact immunogenicity,
because recent studies suggest that egg-derived mutations in vaccine strains can have this
effect (Skowronski et al., 2014).
In this study, we have displayed the relative ease that recent H3N2 clinical
isolates mutate with when propagated in MDCK cell culture. Mutations arising in either
HA or NA can alter antigenic properties of these viruses and mask the true identity of the
originally collected isolate. Better strategies for expanding these poorly growing
influenza isolates and for analyzing their antigenic properties are required in order to
ensure accurate viral surveillance and proper selection of vaccine strains.

MATERIALS AND METHODS
Isolate Collection and Expansion
Respiratory secretions were collected from the nasopharnyx of 10 sick children
(ages 1 month to 7 years old) at the Children’s Hospital of Philadelphia for routine
diagnostic purposes during the 2012-2013 influenza season. All samples were tested and
confirmed to be infected with H3N2 influenza virus. Leftover, de-identified samples were
then sent to us for expansion in MDCK cells, a common cell line used for influenza
propagation (Krauss et al., 2012). Isolates were passaged twice on MDCK cells using
serum-free Minimum Essential Medium (MEM) containing 0.1% L-(tosylamido-2phenyl) ethyl chloromethyl ketone (TPCK)-treated trypsin, 0.1% gentamicin, and 0.5% 1
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M HEPES buffer. Cell expansions were incubated at 37°C with 5% CO2 for four days.
Supernatant was collected and cell debris was removed via centrifugation at 2500 rpm for
3 min.

Hemagglutination Assays
MDCK-expanded isolates were serially diluted twofold in a 96-well round-bottom
plate. Then, 12.5 µL of a 2% (vol/vol) turkey RBC solution or a 2.5% (vol/vol) guinea
pig RBC solution were added. Agglutination was read out after incubating for 1 h at room
temperature. For hemagglutination assays looking to determine NA-dependent receptor
binding, oseltamivir was added to each well at a final concentration of 10 µM.

TCID50 Assays
We plated MDCK cells in a 96-well flat-bottom plate at 40000 cells/well in MEM
with 9% fetal bovine serum. Next day, cells were washed twice with serum-free MEM
before adding 180 µL serum-free MEM containing 0.1% TPCK-treated trypsin, 0.1%
gentamicin, and 0.5% 1 M HEPES buffer. MDCK-expanded isolates were then serially
diluted tenfold across the plate. Isolates were run in quadruplicate and pipet tips were
changed for each row. Plates were incubated for 4 d at 37°C with 5% CO2. All wells were
checked for cytopathic effect and TCID50/mL values were calculated.

Sequencing of Isolates
We obtained the HA1 and NA reference sequences of the A/Victoria/361/2011
H3N2 vaccine strain from the EpiFlu database (accession numbers EPI349103 and
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EPI349104, respectively). We extracted RNA from the original clinical samples and the
MDCK-expanded supernatant using the Qiagen QIAamp Viral RNA Mini Kit. One-Step
RT-PCR (Qiagen) using H3N2 HA and NA specific primers was then used to amplify the
influenza HA1 and NA genes of interest. After gel purification of PCR products, Sanger
sequencing was used to sequence all samples. For Isolate 6, enhanced sequencing of the
original clinical sample was performed using TA cloning (TOPO TA Cloning Kit; Life
Technologies) of the PCR products. The P237L HA mutation was mapped on the
crystallized H3 trimer structure (PDB entry 1HGG).

Reverse-Genetics Derived Viruses
We extracted RNA from the A/Victoria/361/2011 vaccine strain and from Isolate
2, and then cloned the HA and NA of each virus into the pHW2000 reverse genetics
plasmid. We inserted the F209S and P237L HA mutations using the QuikChange sitedirected mutagenesis kit (Stratagene). We rescued viruses containing the different HA
genes, the NA of A/Victoria/361/2011 or Isolate 2, and the internal genes of PR8 by
transfecting 293T/MDCK co-cultures as previously described (Hoffmann et al., 2000).
All rescued viruses were then passaged two times in MDCK cells and sequenceconfirmed for stability. Supernatant collected after the second passage was used for
receptor binding avidity and HAI assays.

Receptor Binding Avidity Assays
As previously described (Hensley et al., 2009; Yewdell et al., 1986), guinea pig
RBCs were pre-treated with different amounts of RDE for 1 h at 37°C. The RBCs were
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then washed twice with PBS and added as 2% (vol/vol) solutions to four agglutinating
doses of each virus (as determined using non-treated guinea pig RBCs). Extent of
agglutination was measured after 1 h incubation at room temperature. The viruses with
higher receptor binding avidities are able to bind to RBCs that are treated with higher
amounts of RDE (Hensley et al., 2009; Yewdell et al., 1986).

Hemagglutination Inhibition Assays with Ferret Antisera
Ferret antiserum to A/Victoria/361/2011 (H3N2), FR-1079, was obtained through the
Influenza Reagent Resource, Influenza Division, WHO Collaborating Center for
Surveillance, Epidemiology and Control of Influenza, Centers for Disease Control and
Prevention, Atlanta, GA, USA. Antiserum was serially diluted twofold in PBS in a 96well round-bottom plate. Four agglutinating doses of virus were then added to the diluted
antiserum in a total volume of 100 µL. Next, 12.5 µL of a 2.5% (vol/vol) guinea pig RBC
solution were added. Agglutination was read out after incubating for 1 h at room
temperature. HAI titers are reported as the inverse of the highest dilution that inhibited
hemagglutination of guinea pig RBCs.
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independent experiments. Viruses were compared using one-tailed, unpaired t tests. (C)
HAI assays comparing the WT and P237L reverse-genetics derived viruses were
performed using ferret antisera raised against the A/Victoria/361/11 H3N2 vaccine strain.
Experiment was conducted three independent times and all raw HAI titers are displayed.
(D) The frequencies of P237 (black) and L237 (orange) were determined after TA
cloning of the PCR product amplified from the original clinical material of Isolate 6. A
total of 21 clones were sequenced following TA cloning.
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Table 1

TABLE 1 Infectious and HAU titers of expanded clinical isolatesa
Isolate
no.
TCID50/ml
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5
6
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8
9
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4
4
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Isolate 2 F209S H
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a
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Shown are infectious (TCID50/ml) and agglutination (HAU) titers after clinical
isolates were passaged twice on MDCK cells. Oselt, oseltamivir.

RBCs previou
stroying enzym
NA-dependent viral attachment (9, 10). These NA mutations removes sialic
Clinical isolates collected from H3N2-infected children at the Children’s Hospital of
were not detected in the original clinical isolates, which is con- with the P23
sistent with
sequencing
studies
(17). The
isolate that
Philadelphia
were previous
passaged twice
on MDCK cells.
Supernatant
was collected
and testedtreated with
agglutinated RBCs via an NA-independent mechanism (isolate (Fig. 1B), ind
for infectious titer (TCID50/mL) and hemagglutination units (HAU). HAU titers are
6) did not acquire an NA mutation following MDCK expansion binding avidit
erated agains
but did
acquire
a single
mutation
residue
237.results
Thisinisoreported
as the
maximum
dilutionHA
of expanded
viralat
isolates
that still
full
late also uniquely possessed an F209S HA mutation, which was source, Atlant
agglutination
of 12.5 µL
of after
2% (vol/vol)
turkey
RBCs or 2.5%
guinea
pig
mutation had
present before
and
MDCK
expansion.
We(vol/vol)
did not
detect
HA or NA mutations in the five MDCK-expanded viral isolates with previous
RBCs. Agglutination was also determined in the presence of 10 µM oseltamivir (Oselt.)
avidity are dif
that grew to low titers and agglutinated RBCs poorly.
to detect
Eachreverse-genetics
isolate was placed studies
into one of
categories Sanger sequen
WeNA-dependent
completed binding.
additional
tofour
determine
if the P237L or F209S HA mutation promoted enhanced growth in the original
based on its ability to grow, to agglutinate RBCs, and whether agglutination was NAand agglutination of isolate 6. We used a QuikChange kit we were able t
(Stratagene,
La Jolla, CA) to introduce each of these mutations clinical isolate
dependent
or NA-independent.
into the HAs of the A/Victoria/361/11 H3N2 vaccine strain and cloning (TOP
isolate 2. We chose isolate 2 for reverse-genetics experiments, CA) of PCR p
Taken toge
since this isolate agglutinates poorly (Table 1). We rescued
virus using A/Puerto Rico/8/1934 (PR8) internal genes and the strains replica
NA of either A/Victoria/361/1137	
  
or isolate 2 after transfecting ther HA or N
293T/MDCK cocultures as previously described (18). Viruses antigenic testi
engineered to have the P237L mutation, but not the F209S agglutination
mutation, grew to high titers and agglutinated RBCs in the goal of HAI as
presence of oseltamivir (Table 3). P237 is located in the HA fore it is diffic
Table 1. Infectious and HAU titers of expanded clinical isolates.

38	
  

D151G
D151N
D151G
D151G
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Q49R, N161S, N294K
Q49R, T144A, R158G, N161S, Q189H, N294K
Q49R, T144A, R158G, N161S, N294K
R158G, N161S, N294K
Q49R, T144A, R158G, N161S, F209S, N294K P237L
T144A, R158G, N160S, N161S, N294K
Q49R, N161S, N294K
Q49R, N161S, N294K
Q49R, N161S, N294K

NA mutations upon Differences in HA sequence from that of the
MDCK expansion
H3N2 vaccine strainb

Mutations that arose upon MDCK expansion are in bold.
Sequences were compared to that of the A/Victoria/361/11 2012-2013 vaccine strain (linear numbering).
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K128R, V143M, K258E, T329N
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Isolate
no.
Category

HA mutation upon
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cloning (TOPO TA Cloning kit; Life Technologies, Carlsbad,
CA) of PCR products (Fig. 1D).
Taken together, our data indicate that recent clinical H3N2
strains replicate poorly in MDCK cells and rapidly acquire either HA or NA mutations when propagated in vitro prior to
antigenic testing. These mutations increase virus growth and
agglutination titers and can potentially skew HAI assays. The
goal of HAI assays is to detect HA antigenic changes, and therefore it is difficult to interpret data when agglutination is mediated by mutated NAs. The addition of oseltamivir directly into
HAI assays may circumvent this problem (9). We have previously shown that HA mutations that alter receptor binding
avidity can skew antigenic maps based on HAI assays (20), and

TABLE 2 Differences in sequences of clinical isolates before and after MDCK expansiona

into the HAs of the A/Victoria/361/11 H3N2 vaccine strain and
isolate 2. We chose isolate 2 for reverse-genetics experiments,
since this isolate agglutinates poorly (Table 1). We rescued
virus using A/Puerto Rico/8/1934 (PR8) internal genes and the
NA of either A/Victoria/361/11 or isolate 2 after transfecting
293T/MDCK cocultures as previously described (18). Viruses
engineered to have the P237L mutation, but not the F209S
mutation, grew to high titers and agglutinated RBCs in the
presence of oseltamivir (Table 3). P237 is located in the HA
trimer interface (Fig. 1A), and it is possible that this mutation
affects sialic acid binding by stabilizing the HA trimer. We
determined the relative receptor avidities of viruses possessing
either P237 or L237 by completing agglutination assays with
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Table 2. Differences in sequences of clinical isolates before and after MDCK
expansion.
We sequenced the HA1 and NA genes of each original clinical isolate and twice MDCKexpanded isolate and compared the sequences to the A/Victoria/361/11 H3N2 vaccine
strain (EpiFlu accession numbers EPI349103 and EPI349104). Multiple differences in
both HA and NA compared to the H3N2 vaccine strain were detected for all original
clinical isolates. Upon expansion, mutations arose at NA residue 151 and HA residue 237
(shown in bold). Isolates are grouped top to bottom depending on their agglutination
“Category” (classifications described in Table 1).
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3
#2
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a

Shown are infectious (TCID50/ml) and agglutination (HAU) titers. Oselt, oseltamivir.

Table 3. Infectious and HAU titers of reverse-genetics viruses.
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mutation had reduced HAI titers (Fig. 1C), which is consistent
with previous studies demonstrating that viruses with higher
avidity are difficult to inhibit in HAI assays (3, 19, 20). Using
Sanger sequencing, we did not detect the P237L HA mutation
in the original clinical material of isolate 6 (Table 2); however,
we were able to detect low levels of this mutation in the original
clinical isolate after sequencing individual clones following TA
cloning (TOPO TA Cloning kit; Life Technologies, Carlsbad,
CA) of PCR products (Fig. 1D).
Taken together, our data indicate that recent clinical H3N2
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antigenic testing. These mutations increase virus growth and
agglutination titers and can potentially skew HAI assays. The
goal of HAI assays is to detect HA antigenic changes, and thereWe used reverse genetics to rescue viruses with the WT, F209S, or P237L mutations in
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CHAPTER 3 – IDENTIFICATION OF THE MUTATIONS
RESPONSIBLE FOR THE ANTIGENIC DRIFT OF H3N2
INFLUENZA VIRUSES DURING THE 2014-2015 SEASON

Parts of this chapter were previously published in:

Chambers BS, Parkhouse K, Ross TM, Alby K, and Hensley SE. (2015) Identification of
hemagglutinin residues responsible for H3N2 antigenic drift during the 2014-2015
influenza season. Cell Reports 12:1-6.

SUMMARY
Influenza vaccines must be updated regularly because influenza viruses
continuously acquire mutations in the antibody binding sites of hemagglutinin (HA). The
majority of H3N2 strains circulating in the Northern Hemisphere during the 2014-2015
season were antigenically mismatched to the A/Texas/50/2012 H3N2 vaccine strain.
H3N2 strains that circulated during that season possessed several new HA mutations that
arose after selection of the vaccine strain, and it was unknown which of these mutations
contributed to the 2014-2015 vaccine mismatch. Here, we used reverse genetics to
demonstrate that mutations in HA antigenic site B were primarily responsible for the
vaccine mismatch. Antisera isolated from vaccinated humans and infected animals had
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reduced hemagglutination inhibition and in vitro neutralization titers against reversegenetics-derived viruses possessing mutations in HA antigenic site B. These data provide
an antigenic explanation for the low influenza vaccine efficacy observed during the 20142015 influenza season. Furthermore, our data supported the World Health Organization’s
decision to update the H3N2 component of the vaccine for the 2015-2016 influenza
season.

INTRODUCTION
Most neutralizing influenza antibodies (Abs) target the hemagglutinin (HA)
glycoprotein, and therefore, influenza vaccines are designed to elicit anti-HA Abs.
However, these vaccines are ineffective when viruses acquire mutations in the Ab
binding sites of HA (Yewdell, 2011). Mid-season influenza vaccine efficiency rates
during the 2014–2015 Northern Hemisphere season were extremely low (Flannery et al.,
2015; Pebody et al., 2015), and the H3N2 strains that circulated during that season were
antigenically distinct compared to the 2014-2015 A/Texas/50/2012 H3N2 vaccine strain
(D'Mello et al., 2015b). The 2014-2015 H3N2 strains were grouped into three genetically
distinct clades (Broberg et al., 2015). Viruses within each genetic clade possessed several
shared and unique HA mutations, and it was unclear, at the time, which of these
mutations were antigenically relevant.
H3 HAs have at least five distinct antigenic sites, named HA antigenic sites A-E
(Wiley et al., 1981). Seasonal influenza vaccine strains are routinely chosen based on
antigenic analyses that utilize antisera prepared in previously naïve ferrets (Stöhr et al.,
2012). Koel and colleagues recently demonstrated that most Ab responses from
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previously naïve ferrets infected a single time with an H3N2 virus are heavily focused on
H3 antigenic sites A and B (Koel et al., 2013). Our studies and others have demonstrated
that prior H1N1 influenza exposures can influence the specificity of Ab responses raised
against new H1N1 influenza strains (Hensley, 2014; Li et al., 2013b; Linderman et al.,
2014). We found that ferret antisera do not always recapitulate the different types of
H1N1 Ab specificities that are found in individual humans with vastly different preexposure histories. Human Ab responses appear to be focused on HA antigenic site A of
some H3 strains (Abe et al., 2004) and on HA antigenic site B of other H3 strains
(Popova et al., 2012).
It is important to determine which HA residues were responsible for the observed
antigenic drift of 2014-2015 H3N2 strains. This information can be useful for guiding the
selection of viral strains for future vaccine formulations. Here, we completed serological
assays using A/Texas/50/2012 H3N2 viruses engineered to have specific HA mutations
that were present in H3N2 strains that circulated during the 2014-2015 influenza season.
We found that mutations in H3 antigenic site B significantly decrease the binding of
ferret, sheep, and human Abs elicited by the A/Texas/50/2012 H3N2 vaccine strain. The
World Health Organization (WHO) recommended that the H3 component of seasonal
influenza vaccines should be updated to include A/Switzerland/9715293/2013-like strains
(Anonymous, 2015). Our data supported this recommendation, although we note that the
majority of H3N2 strains circulating at the time had a distinct HA antigenic site B
compared to the A/Switzerland/9715293/2013 strain.
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RESULTS
2014-2015 H3N2 viruses possessed several HA mutations
The H3N2 component of the 2014-2015 influenza vaccine was A/Texas/50/2012,
which belongs to HA genetic clade 3C.1 (Broberg et al., 2015). During the 2014-2015
season, H3N2 strains belonging to phylogenetic HA clades 3C.2a, 3C.3, and 3C.3a
predominated (Broberg et al., 2015). Compared to the A/Texas/50/2012 vaccine strain,
clade 3C.2a viruses possessed HA differences L3I, N144S, N145S, F159Y, K160T,
N225D, and Q311H; clade 3C.3 viruses possessed HA differences T128A, R142G, and
N145S; and clade 3C.3a viruses possessed HA differences T128A, A138S, R142G,
N145S, F159S, and N225D (Table 4). HA clade 3C.2a and 3C.3a viruses were
antigenically distinct compared to the A/Texas/50/2012 strain and the WHO
recommended that the H3N2 component should be updated with an
A/Switzerland/9715293/2013-like (HA clade 3C.3a) virus for the Northern Hemisphere
2015-2016 vaccine (Anonymous, 2015). Analyses of HA sequences deposited in the
Global Initiative on Sharing All Influenza Data (GISAID) database revealed that the
majority of H3N2 viruses circulating in the United States in the fall and winter of 2014
belonged to HA clade 3C.2a (Fig. 4A). We performed a similar analysis for Philadelphiaarea H3N2 viruses using clinical isolates collected from the Hospital of the University of
Pennsylvania. Primary isolates were directly sequenced and revealed a similar
distribution of circulating genetic clades during the 2014-2015 influenza season as
compared to the GISAID database sequences (Fig. 4B).
To understand the antigenic basis for the extremely poor H3N2 vaccine match
during the 2014–2015 influenza season, we created a panel of A/Texas/50/2012 viruses
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that possessed the HA mutations found in HA clade 3C.2a, 3C.3, and 3C.3a viruses
(Table 5). We then completed antigenic analyses using antisera isolated from ferrets,
sheep, and humans exposed to the A/Texas/50/2012 H3N2 vaccine strain (Tables 6 and
7). Our mutant viral panel included every mutation from Table 4 that is located in the HA
globular head (Fig. 4C), with the exception of the F159Y and K160T mutations. We were
able to successfully rescue A/Texas/50/2012 viruses that possessed the F159Y and
K160T mutations, but these viruses failed to agglutinate red blood cells (RBCs) and
quickly mutated at HA residue 160 when propagated for antigenic analyses. However, we
were still able to assess the antigenic relevance of mutations in this epitope of HA
because our mutant panel included a virus with the F159S HA mutation.

Ferrets and sheep infected with A/Texas/50/2012 mount Abs against HA antigenic site B
We first completed hemagglutination-inhibition (HAI) assays with our mutant
A/Texas/50/2012 virus panel and antisera collected from ferrets and sheep recovering
from primary A/Texas/50/2012 infections (Table 6). As expected, anti-A/Texas/50/2012
Ab titers were drastically decreased using the antigenically distinct
A/Switzerland/9715293/2013 clade 3C.3a virus. Strikingly, anti-A/Texas/50/2012 Ab
titers were reduced fourfold in HAI assays against viruses engineered to possess the
F159S HA mutation (Table 6). HA residue 159 is located in a highly exposed region of
HA antigenic site B in H3 HAs (Fig. 4C). Other HA mutations had more subtle effects on
anti-A/Texas/50/2012 HAI titers. For example, the A138S and N145S HA mutations
each lead to twofold decreases in HAI titers. We have previously shown that viruses that
bind to RBCs with a high avidity can escape Abs in HAI assays independent of antigenic
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change (Li et al., 2013a). We found that A138S and N145S HA mutant viruses bound to
RBCs with a higher avidity (Table 5), and the apparent decrease in HAI titer using these
viruses likely results from this increase in receptor binding avidity. We found that viruses
possessing the F159S HA mutation bound to RBCs with a decreased avidity (Table 5),
and for this reason, we concluded that reduced HAI titers using this virus were the result
of a genuine antigenic change.
To verify the antigenic relevance of the F159S HA mutation, we completed direct
Ab ELISA binding assays with plates coated with virus-like particles (VLPs) possessing
A/Texas/50/2012-WT HA or A/Texas/50/2012-F159S HA (Fig. 5). As a control, we
coated plates with VLPs possessing the antigenically distinct A/Port Chalmers/1/1973
HA (an H3N2 virus from 1973) as well. Antisera isolated from ferrets infected with
A/Texas/50/2012 had reduced binding to VLPs possessing A/Texas/50/2012-F159S HA
compared to VLPs possessing A/Texas/50/2012-WT HA (Fig. 5A). We verified that
equal amounts of VLPs were used in these assays by completing additional ELISA
experiments with the F49 monoclonal antibody (mAb) that recognizes the conserved
stalk region of H3 (Fig. 5B). Collectively, these studies indicate that ferrets and sheep
mount Ab responses against an HA epitope involving HA residue F159 following
infection with A/Texas/50/ 2012, and for this reason we focused the rest of antigenic
analyses on this region of HA.

Ferrets and sheep infected with A/Switzerland/9715293/2013 mount Ab responses that
are not focused against the HA epitope involving HA residue 159
We also completed HAI assays using our mutant viral panel and antisera isolated
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from sheep infected with A/Switzerland/9715293/2013 H3N2 virus. Antisera isolated
from A/Switzerland/9715293/2013-infected animals reacted to all mutant
A/Texas/50/2012 viruses, including viruses that possessed the HA antigenic site B F159S
mutation (Table 6). Therefore, the F159S HA mutation results in an asymmetrical
antigenic change. These data are important because A/Switzerland/9715293/2013 (an HA
clade 3C.3a virus) was chosen as the H3 component of 2015-2016 seasonal vaccines
(Anonymous, 2015), even though HA clade 3C.2a viruses predominated toward the end
of the 2014-2015 influenza season (Fig. 4A) and have continued to dominate circulation
since. And although HA antigenic site B differs between HA clade 3C.3a and 3C.2a
viruses (Table 4), these initial results indicated that vaccinating with an
A/Switzerland/9715293/2013-like virus should elicit an Ab response effective against the
HA clade 3C.2a viruses dominating circulation.

Antisera isolated from most humans vaccinated with A/Texas/50/2012 possess Abs
against HA antigenic site B
Next, we wanted to determine whether human Abs elicited against
A/Texas/50/2012 have the same specificity for HA antigenic site B as we observed in
ferret and sheep antisera. We completed HAI assays using the A/Texas/50/2012-WT and
A/Texas/50/2012-F159S viruses, along with human sera collected pre- and postvaccination with the 2014-2015 seasonal influenza vaccine, which contained the
A/Texas/50/2012 H3N2 vaccine strain. Even before vaccination, over half of the
individuals presented detectable titers against the A/Texas/50/2012-WT virus (Table 7).
This is likely because the A/Texas/50/2012 strain had been in seasonal influenza vaccines
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since the 2013-2014 season and thus many people would have been exposed to this strain
previously. Following vaccination, most individuals (87.5%) either mounted or
maintained Abs that had reduced reactivity against the A/Texas/50/2012-F159S mutant
virus (Table 7). Even in a cohort that covers a fairly large age range (21-50 years old), the
majority of individuals mounted anti-A/Texas/50/2012 Ab responses focused on HA
antigenic site B. It is important to point out however, that some individuals (12.5%) in
this cohort did not possess detectable levels of Abs against HA antigenic site B although
they mounted high responses against the A/Texas/50/2012-WT virus (Table 7). It is
possible that these individuals have an Ab response targeted against another HA antigenic
epitope due to unique pre-exposure histories that shaped their Ab response, similar to
what we have seen previously in certain age groups that possess altered
immunodominance of H1N1 Ab responses (Li et al., 2013b; Linderman et al., 2014).

Anti-A/Texas/50/2012 HA antigenic site B Abs are neutralizing
Although we established that the majority of ferret, sheep, and human Abs against
A/Texas/50/2012 targeted HA antigenic site B, it wasn’t known whether these Abs were
neutralizing. To determine the functional consequence of the F159S HA mutation, we
completed in vitro neutralization assays with A/Texas/50/2012-WT and
A/Texas/50/2012-F159S viruses using sera samples isolated from humans 21 days postvaccination. We focused on samples that had the largest HAI differences using
A/Texas/50/2012-WT and A/Texas/50/2012-F159S (Table 7). We also completed in vitro
neutralization assays with antisera collected from ferrets 19 days after infection with
A/Texas/50/2012. Overall, the in vitro neutralization data mirrored our HAI results, with
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all seven human sera samples and the ferret sera sample presenting dramatically reduced
neutralization titers against the A/Texas/50/2012-F159S virus compared to the
A/Texas/50/2012-WT virus (Table 8). These results indicate that the antiA/Texas/50/2012 Abs targeted against HA antigenic site B in humans and ferrets are
neutralizing, and that a single mutation at HA residue F159 can abrogate neutralization
by these Abs.

DISCUSSION
There was a clear H3N2 vaccine mismatch during the 2014-2015 influenza season
(Broberg et al., 2015; D'Mello et al., 2015a; Flannery et al., 2015; Pebody et al., 2015),
and it is important to identify the specific HA mutations that led to this mismatch. This
information could be crucial for properly selecting viral strains to be used in future
vaccine formulations. In this report, we demonstrated that sheep, ferrets, and humans
exposed to the 2014-2015 A/Texas/50/2012 H3N2 vaccine strain mount Ab responses
that are targeted against HA antigenic site B. The majority of H3N2 viruses circulating
during the 2014-2015 season possessed differences in HA antigenic site B compared to
the vaccine strain (Fig. 4).
Our previous studies indicate that the specificity of human H1N1 Ab responses is
shaped by prior H1N1 exposures (Li et al., 2013b; Linderman et al., 2014). We found that
most human H1N1 Ab responses are narrowly focused on epitopes that were present in
viral strains that circulated during each individual’s childhood. It is unclear whether prior
H3N2 exposures influence the development of Ab responses to drifted H3N2 strains in a
similar manner. Our data indicate that most 21 to 50 year old humans mount anti49	
  

A/Texas/50/2012 Abs against HA antigenic site B following vaccination. It is important
to note that some vaccinated individuals in our study (4 out of 32) mounted antiA/Texas/50/2012 Ab responses that were not directed against HA antigenic site B
(antisera from these four individuals had <twofold change in HAI titer using the
A/Texas/50/2012-WT and A/Texas/50/2012-F159S viruses). Current studies are under
way to investigate whether these four individuals have evidence of unique H3N2
exposures.
The WHO recommended that the H3N2 component of the 2015-2016 seasonal
vaccine should be updated to include the A/Switzerland/9715293/2013 strain
(Anonymous, 2015). We note that this clade 3C.3a virus differs in HA antigenic site B
compared to clade 3C.2a viruses, which predominated toward the end of the 2014-2015
Northern Hemisphere influenza season (Fig. 4). Clade 3C.2a viruses possess an
additional predicted glycosylation site in HA antigenic site B due to S159Y and K160T
HA differences compared to A/Switzerland/9715293/2013. The addition of a new
glycosylation site on top of the HA antigenic site B could potentially alter antigenicity
and Ab access to this region of HA. In our studies, sera isolated from
A/Switzerland/9715293/2013-infected animals reacted equally to the
A/Switzerland/9715293/2013 strain and our A/Texas/50/2012 mutant panel; however,
additional studies would need to be completed to precisely define the specificity of Abs
elicited by A/Switzerland/9715293/2013 exposure.
Taken together, our data suggest that mutations in HA antigenic site B of 20142015 H3N2 strains led to a major antigenic change. This antigenic change is likely
responsible for the low vaccine efficacy during the 2014-2015 season. Our studies
50	
  

support the WHO’s decision to update the H3N2 component of the 2015-2016 influenza
vaccine.

MATERIALS AND METHODS
HA Sequences
We obtained HA sequence data from the GISAID website
http://platform.gisaid.org/epi3/. We grouped all human isolates collected by United States
surveillance labs between June 1, 2014 and January 31, 2015 into clades based on HA
genetic sequence. All isolates from the Hospital of the University of Pennsylvania were
sequenced and compared to the HA sequence of A/Texas/50/2012, EpiFlu accession
number EPI408131.

Clinical Isolates
Respiratory secretions were collected from H3N2-infected patients at the Hospital
of the University of Pennsylvania between December 2014 and January 2015. RNA was
extracted directly from clinical isolates using the Qiagen QIAamp Viral RNA Mini Kit
and the HA1 gene was amplified via RT-PCR using H3-specific primers. Sequences were
aligned to A/Texas/50/2012 for comparison of HA1 sequence differences.

Viruses
We obtained the A/Switzerland/9715293/2013 strain from the National Institute
for Biological Standards and Control (NIBSC) in Hertfordshire, UK. We created reversegenetics derived viruses that possessed the A/Texas/50/2012 HA. Because we did not
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have the A/Texas/50/2012 strain when we initiated these experiments, we extracted RNA
from the A/Victoria/361/2011 strain and cloned the HA of this virus into the pHW2000
reverse genetics plasmid. We then used QuikChange site-directed mutagenesis kits
(Stratagene) to convert the A/Victoria/361/2011 HA sequence to the A/Texas/50/2012
HA sequence (by adding T128N, G186V, S198P, S219F, N278K HA mutations). We
then introduced the additional HA mutations from Table 5 into this A/Texas/50/2012 HA
sequence. We rescued viruses that possessed the different mutated A/Texas/50/2012 HAs
after transfecting 293T/MDCK cell co-cultures with the different HA plasmids and
plasmids derived from PR8 that encoded for the rest of the influenza genome. All viruses
used for antigenic analyses were propagated in 10-day-old fertilized chicken eggs. We
used Sanger sequencing to verify that additional mutations did not arise during viral
propagation.

Antisera
All sheep antisera used in this study were obtained from the National Institute for
Biological Standards and Control (NIBSC) in Hertfordshire, UK. Antisera were collected
from sheep 28 days post-infection. Ferret antisera used in this study were obtained from
the Influenza Reagent Resource, Influenza Division, WHO Collaborating Center for
Surveillance, Epidemiology and Control of Influenza, CDC, Atlanta, GA. Antisera were
collected from ferrets 19 days post-infection. Antisera were also collected from humans
prior to vaccination (d0) and 21 days following vaccination with the 2014-2015 seasonal
influenza vaccine. All studies involving the collection and analysis of human sera were
approved by the institutional review boards of the Wistar Institute and Vaccine and Gene
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Therapy Institute of Florida (VGTI). All sera were treated with receptor-destroying
enzyme (RDE) for 3 h prior to antigenic testing.

HAI Assays
HAI titrations were performed in 96-well round-bottom plates. Sera were serially
diluted twofold and added to four agglutinating doses of virus in a total volume of 100
µL. Next, 12.5 µL of a 2% (v/v) turkey RBC solution were added. Agglutination was read
out after incubating for 1 h at room temperature. HAI titers were recorded as the inverse
of the highest dilution that inhibited hemagglutination of turkey RBCs. Similar results
were obtained using guinea pig RBCs.

ELISA Assays
VLPs expressing A/Texas/50/2012-WT HA, A/Texas/50/2012-F159S HA, or
A/Port Chalmers/1/1973 HA were created. Codon-optimized sequences were cloned into
the pCMV-Sport6 plasmid. VLPs were rescued by transfecting 293T cells with plasmids
expressing HIV gag, PR8 NA, HAT (a human airway trypsin-like protease), and each
HA. VLPs isolated from culture supernatants were concentrated using a 20% sucrose
cushion and resuspended in PBS. VLP amounts were normalized in ELISAs using the
F49 mAb (Clontech) that binds to a conserved region of the H3 stalk. Goat anti-ferret
immunoglobulin G (IgG) conjugated to horseradish peroxidase (Abcam) was used to
detect binding of A/Texas/50/2012 ferret antisera and goat anti-mouse IgG conjugated to
horseradish peroxidase (MP Biomedicals) was used to detect the murine F49 mAb.
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Neutralization Assays
In vitro neutralization assays were performed in 96-well flat-bottom plates. Sera
were serially diluted twofold and then added to 100 TCID50 units of A/Texas/50/2012WT or A/Texas/50/2012-F159S virus and incubated at room temperature for 30 min. The
virus-sera mixtures were then incubated with MDCK cells for 1 h at 37°C. Next, cells
were washed, and then serum-free media with TPCK-treated trypsin, HEPES, and
gentamicin was added. We visually determined cytopathic endpoints 3 days later. Data
are expressed as the inverse of the highest dilution that caused neutralization.

Receptor Binding Assays
As previously described (Hensley et al., 2009; Li et al., 2013a), turkey RBCs were
pre-treated with different amounts of RDE (a neuraminidase) for 1 h at 37°C. The RBCs
were washed with PBS and added (as 2% v/v solutions) to four agglutinating doses of
each virus (as determined using non-treated RBCs). After incubating 1 h at room
temperature, agglutination was measured. Viruses with higher receptor binding avidities
are able to bind to RBCs that are treated with higher amounts of RDE (Hensley et al.,
2009; Li et al., 2013a; Yewdell et al., 1986).
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(TableData
3). Importantly,
we wereof two
influenza
season (Broberg et al., 2015; D
able to detect antigenic site B-specific Ab responses in humans nery et al., 2015; Pebody et al., 2015
experiments.
that represent a fairly large age range (21–50 years old). It is inter- identify specific HA mutations that hav
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Table 4

from ferrets and
infections (Table 2).
Clades
were drastically d
3C.2a
3C.3
3C.3a
A/Switzerland/9715
L3I
A/Texas/50/2012 A
T128A
T128A
with viruses engine
A138S
(Table 2). Residue
antigenic site B of
R142G
R142G
more subtle effec
N144S
example, the A138
N145S
N145S
N145S
2-fold decreases in
F159Y
F159S
that bind to red blo
K160T
HAI assays indepe
N225D
N225D
We found that A13
Q311H
blood cells with a
Shown are HA residues (H3 numbering) that differ between the A/Texas/
decreased HAI tite
50/2012 H3N2 vaccine strain and most clade 3C.2a, 3C.3, and 3C.3a
increase in recept
viruses isolated during the 2014–2015 Northern Hemisphere influenza
possessing the F15
Table
4. HA sequence differences between newly emerged clades and the
season.
decreased avidity (
that reduced HAI
A/Texas/50/2012 vaccine strain.
genuine antigenic c
Shown
are
HA
residues
(in
H3
numbering)
that
differ
between
the
A/Texas/50/2012
To verify the ant
strains belonging to the phylogenetic 3C.2a, 3C.3, and 3C.3a HA
clades predominated (Broberg et al., 2015). Compared to the we completed add
H3N2 vaccine strain and most HA clade 3C.2a, 3C.3, and 3C.3a viruses isolated during
A/Texas/50/2012 strain, 3C.2a viruses possess HA differences plates coated wi
L3I, N144S,
F159Y,
K160T,
N225D, and Q311H, A/Texas/50/2012-W
theat
2014-2015
NorthernN145S,
Hemisphere
influenza
season.
3C.3 viruses possess HA differences at T128A, R142G, and ure 1C). As a cont
N145S, and 3C.3a viruses possess HA differences at T128A, the antigenically d
A138S, R142G, N145S, F159S, and N225D (Table 1). HA clade a 1973 H3 virus)
3C.2a and 3C.3a viruses are antigenically distinct compared to with A/Texas/50/2
the A/Texas/50/2012 strain and the World Health Organization ing A/Texas/50/201
has recommended that the H3N2 component should be updated A/Texas/50/2012-W
with an A/Switzerland/9715293/2013-like (HA 3C.3a) virus for amounts of VLPs
the Northern Hemisphere 2015–2016 vaccine (Anonymous, additional ELISA e
body (mAb) that re
2015).
Analyses of HA sequences deposited in the GISAID database (Figure 1D). Colle
revealed that the majority of H3N2 viruses circulating in the and sheep moun
United States in the fall and winter of 2014 belong to HA clade involving residue
3C.2a (Figure 1A). To understand58	
  the antigenic basis for the 2012, and for this
extremely poor H3N2 vaccine match during the 2014–2015 influ- alyses on this regi
enza season, we created a panel of A/Texas/50/2012 viruses
that possessed HA mutations found in clade 3C.2a, 3C.3, and Ferrets and Shee
3C.3a viruses (Table S1), and we completed antigenic analyses 9715293/2013 M
Table 1. HA Mutations in 2014–2015 H3N2 Viruses

Table 5
viruses
A/Texas/50/2012-WT
A/Texas/50/2012-N128A
A/Texas/50/2012-A138S
A/Texas/50/2012-R142G
A/Texas/50/2012-N144S+N145S
A/Texas/50/2012-N145S
A/Texas/50/2012-F159S
A/Texas/50/2012-N225D
A/Switzerland/9715293/2013

relative receptor binding avidity
++
++
+++
++
++
+++
+
+++
+++

Table S1: Mutant viral panel and receptor binding avidities, related to Table 2.
Shown
are the
reverse
genetics-derived mutant
thatand
we created
for our antigenic
Table
5. Our
panel
of A/Texas/50/2012
mutantpanel
viruses
their relative
binding

analyses. Relative receptor binding avidity is also shown (+++ indicates virus was able to
agglutinate red blood cells treated with > 1.0 ug/mL RDE; ++ indicates virus was able to
avidities.
agglutinate red blood cells treated with 0.5-1.0 ug/mL RDE; + indicates virus was able to
agglutinate red blood cells treated with <0.5 ug/mL RDE). Data are representative of 2
Shown
is the panel
of reverse-genetics derived mutant viruses that we created for our
independent
experiments.

!
antigenic analyses. Relative receptor binding avidity is also shown (+++ indicates virus

was able to agglutinate RBCs treated with > 1.0 ug/mL RDE; ++ indicates virus was able
to agglutinate RBCs treated with 0.5-1.0 ug/mL RDE; + indicates virus was able to
agglutinate RBCs treated with <0.5 ug/mL RDE). Data are representative of two
independent experiments.
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960
1,280
480
640
1,280
480
240
640
60

A/Texas/50/12-WT

A/Texas/50/12-N128A

A/Texas/50/12-A138S

A/Texas/50/12-R142G

A/Texas/50/12-N144S+N145S

A/Texas/50/12-N145S

A/Texas/50/12-F159S

A/Texas/50/12-N225D

A/Switzerland/9715293/13

1,280

7,680

3,840

5,120

10,240

7,680

5,120

10,240

10,240

Sheep a-A/Texas/50/12

2,560

2,560

3,840

1,920

3,840

1,920

1,280

2,560

2,560

Sheep a-A/Switzerland/9715293/13

This information is crucial for properly selecting viral strains
to be used in future vaccine formulations. In this report, we
demonstrate that sheep, ferrets, and humans exposed to the
2014–2015 A/Texas/50/2012 H3N2 vaccine strain mount Ab
responses that are targeted against HA antigenic site B. The majority of H3N2 viruses circulating during the 2014–2015 season
possessed mutations in antigenic site B (Figure 1A).
Our previous studies indicate that the specificity of human
H1N1 Ab responses is shaped by prior H1N1 exposures (Li
et al., 2013b; Linderman et al., 2014). We found that most human
H1N1 Ab responses are narrowly focused on epitopes that were
present in viral strains that circulated during each individual’s
childhood. It is unclear whether prior H3N2 exposures influence

HA Sequences
We obtained HA sequence data from the GISAID website http://platform.
gisaid.org/epi3/. Information related to the viral isolates used for these studies
is reported in Table S3.

EXPERIMENTAL PROCEDURES

Taken together, our data suggest that mutations in antigenic
site B of 2014–2015 H3N2 strains have led to a major antigenic
change. This antigenic change is likely responsible for the low
vaccine efficacy during the 2014–2015 season. Our studies support the World Health Organization’s decision to update the
H3N2 component of the 2015–2016 influenza vaccine.

HAI assays were completed using antisera isolated from ferrets 19 days post-infection or sheep 28 days post-infection. Data are representative of
three independent assays.

Ferret a-A/Texas/50/12

Viruses

Sera

Table 2. Analyses of Ferret and Sheep Anti-sera Raised against the A/Texas/50/2012 and the A/Switzerland/9715293/13 Strains

Table 6

Table 6. Analyses of ferret and sheep antisera raised against the A/Texas/50/2012
and A/Switzerland/9715293/2013 vaccine strains.
HAI assays were completed using the A/Texas/50/2012-WT virus and the panel of
A/Texas/50/2012 mutant viruses, as well as the A/Switzerland/9715293/2013 WT (HA
clade 3C.3a) virus as a control. Antisera were collected from ferrets 19 days postinfection and from sheep 28 days post-infection. Data are representative of three
independent assays.
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Table 3. Analyses of Sera Isolated from Humans Pre- and Post-

Table
7
vaccination
with the 2014–2015 Seasonal Influenza Vaccine that
Includes the A/Texas/50/2012 Vaccine Strain
Pre-vaccination

Post-vaccination

Sample
ID

Age
(years)

A/Texas/
50/2012

A/Texas/50/
2012-F159S

A/Texas/
50/2012

A/Texas/50/
2012-F159S

01

21

240

40

160

40

02

23

640

240

320

160

03

24

240

80

240

80

04

25

240

80

240

80

05

26

80

<40

640

320

06

27

480

<40

320

<40

07

29

60

<40

120

40

08

30

60

40

80

40

09

30

<40

<40

640

320

10

30

320

240

640

480

11

31

320

80

320

120

12

31

40

<40

60

<40

13

31

<40

<40

40

<40

14

31

<40

<40

160

<40

15

31

40

<40

40

<40

16

34

480

60

640

80

17

35

480

80

320

120

18

35

160

80

160

160

19

35

320

240

640

320

20

35

160

<40

240

<40

21

36

60

<40

120

<40

22

38

<40

<40

120

<40

23

38

<40

<40

240

<40

24

39

240

80

320

80

25

41

320

240

320

240

26

44

<40

<40

80

40

27

44

40

<40

80

80

28

46

<40

<40

80

40

29

48

80

<40

160

40

30

48

<40

<40

60

<40

31

48

<40

<40

80

<40

32

50

80

40

160

80

Sera were collected from humans pre- and post-vaccination with the
2014–2015 seasonal influenza vaccine. HAI assays were completed
using A/Texas/50/2012 and A/Texas/50/2012 with the F159S HA mutation. Data are representative of three independent assays.
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sera were treated with receptor-destroying enzyme (RDE) for 3 hr prior to
antigenic testing.
HAI Assays
HAI titrations were performed in 96-well round bottom plates. Sera were
serially diluted 2-fold and added to four agglutinating doses of virus in a total

ELISA Assays
VLPs expressing A/Texas/50/2012-WT HA, A/T
A/Port Chalmers/1/1973 HA were created. C
were cloned into the pCMV-Sport6 plasmid. VLP
ing 293T cells with plasmids expressing HIV gag
HAT (human airway trypsin-like protease), and e
culture supernatants were concentrated using a
resuspended in PBS. VLP amounts were normal
mAb (Clontech) that binds to a conserved regio
ferret immunogloublin G (IgG) conjugated to hors
was used to detect binding of A/Texas/50/2012
mouse IgG conjugated to horseradish peroxid
used to detect the murine F49 mAb.

Neutralization Assays
In vitro neutralization assays were performed in
Sera were serially diluted and then added to 10
50/2012-WT or A/Texas/50/2012-F159S virus and
ature for 30 min. The virus-sera mixtures were the
for 1 hr at 37C. Next, cells were washed, and
TPCK-treated trypsin was added. We visually
points 3 days later. Data are expressed as the in
that caused neutralization.

Receptor Binding Assays
As previously described (Li et al., 2013a), turke
treated with different amounts of RDE (a neura
The red blood cells were washed with PBS and
to four agglutinating doses of each virus (as de
red blood cells). After a 1-hr incubation, agglutina
with higher receptor binding avidities are able to b
treated with high amounts of RDE (Li et al., 2013
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Table 7. Analyses of sera isolated from humans pre- and post-vaccination with the
2014-2015 seasonal influenza vaccine.
HAI assays were completed using the A/Texas/50/2012-WT and A/Texas/50/2012-F159S
viruses. Sera were collected from 32 humans pre-vaccination (d0) and post-vaccination
(d21) with the 2014-2015 seasonal influenza vaccine that contained the A/Texas/50/2012
vaccine strain. Data are representative of three independent assays.
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Table 8
!
human ID 06
human ID 14
human ID 20
human ID 21
human ID 22
human ID 23
human ID 31
ferret anti-A/Texas/50/2012

A/Texas/50/2012-WT
640
1280
640
320
640
320
320
1280

A/Texas/50/2012-F159S
80
80
<40
40
160
80
80
40

Table S2: In vitro neutralization titers using sera isolated from vaccinated humans
and infected
ferrets,
related to titers
Table using
2 and antisera
Table 3. isolated
In vitro neutralization
assays
Table
8. In vitro
neutralization
from vaccinated
were completed using sera isolated 21 days following vaccination of humans with the
2014-2015 influenza vaccine or sera isolated 19 days following infection of ferrets with
humans
and infected ferrets.
the A/Texas/50/2012 strain. Data are representative of 2 independent assays.

In! vitro neutralization assays were completed in MDCK cells using the A/Texas/50/2012WT and A/Texas/50/2012-F159S viruses. Neutralization titers were determined for
antisera isolated 21 days following vaccination of humans with the 2014-2015 influenza
vaccine or antisera isolated 19 days following infection of ferrets with the
A/Texas/50/2012 strain. Human sera samples used here displayed the largest reduction in
HAI titers due to the F159S HA mutation (Table 7). Neutralization titers are expressed as
the inverse of the maximum dilution of sera that results in full neutralization of viral
growth. Data are representative of two independent assays.
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CHAPTER 4: POTENTIAL ANTIGENIC EXPLANATION FOR
ATYPICAL H1N1 INFECTIONS AMONG MIDDLE-AGED ADULTS
DURING THE 2013-2014 INFLUENZA SEASON

Parts of this chapter were previously published in:

*Linderman SL, *Chambers BS, *Zost SJ, Parkhouse K, Li Y, Herrmann C, Ellebedy
AH, Carter DM, Andrews SF, Zheng NY, Huang M, Huang Y, Strauss D, Shaz BH,
Hodinka RL, Reyes-Terán G, Ross TM, Wilson PC, Ahmed R, Bloom JD, and Hensley
SE. (2014) Potential antigenic explanation for atypical H1N1 infections among middleaged adults during the 2013-2014 influenza season. PNAS 111(44):15798-15803.
(* = contributed equally)

SUMMARY
Influenza viruses typically cause the most severe disease in children and elderly
individuals. However, H1N1 viruses disproportionately affected middle-aged adults
during the 2013-2014 influenza season. Although H1N1 viruses had recently acquired
several mutations in the hemagglutinin (HA) glycoprotein, classic serological tests used
by surveillance laboratories indicated that these mutations did not change antigenic
properties of the virus. Here, we show that one of these mutations was located in a region
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of HA targeted by antibodies elicited in many middle-aged adults. We found that over
42% of individuals born between 1965 and 1979 possessed antibodies that recognize this
region of HA. Our findings offer a possible antigenic explanation of why middle-aged
adults were highly susceptible to H1N1 viruses during the 2013-2014 influenza season.
Our data further suggest that a drifted H1N1 strain should be included in future influenza
vaccines to potentially reduce morbidity and mortality in this age group.

INTRODUCTION
Seasonal H1N1 (sH1N1) viruses circulated in the human population for much of
the last century and, as of 2009, most humans had been exposed to sH1N1 strains. In
2009, an antigenically distinct H1N1 strain began infecting humans and caused a
pandemic (Dawood et al., 2009; Garten et al., 2009; Smith et al., 2009). Elderly
individuals were less susceptible to 2009 pandemic H1N1 (pH1N1) viruses because of
cross-reactive antibodies (Abs) elicited by infections with older sH1N1 strains (Garten et
al., 2009; Jacobs et al., 2012; Manicassamy et al., 2010; Skountzou et al., 2010; Xu et al.,
2010). pH1N1 viruses have continued to circulate on a seasonal basis since 2009.
Influenza viruses typically cause a higher disease burden in children and elderly
individuals (Mertz et al., 2013), but pH1N1 viruses caused unusually high levels of
disease in middle-aged adults during the 2013-2014 influenza season (Arriola et al.,
2014; Ayscue et al., 2014; Davila et al., 2014; Epperson et al., 2014). For example, a
significantly higher proportion of individuals aged 30-59 years old were hospitalized in
Mexico with laboratory-confirmed pH1N1 cases in 2013-2014 relative to 2011-2012
(Davila et al., 2014).
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Most neutralizing influenza Abs are directed against the hemagglutinin (HA)
glycoprotein. International surveillance laboratories rely primarily on ferret antisera for
detecting HA antigenic changes (Stöhr et al., 2012). For these assays, sera are isolated
from ferrets recovering from primary influenza infections. Seasonal vaccine strains are
typically updated when human influenza viruses acquire HA mutations that prevent the
binding of sera collected from previously naïve ferrets infected with influenza for the first
time. Our laboratory and others have demonstrated that sera isolated from ferrets
recovering from primary pH1N1 infections are dominated by Abs that recognize an
epitope involving HA residues 156, 157, and 158 of the Sa HA antigenic site (Chen et al.,
2010b; Li et al., 2013b). The pH1N1 component of the seasonal influenza vaccine has not
been updated since 2009 because very few pH1N1 isolates possess mutations in HA
residues 156, 157, and 158. The majority of isolates from the 2013-2014 season have
been labeled as antigenically similar to the A/California/07/2009 vaccine strain (Arriola
et al., 2014).
It is potentially problematic that major antigenic changes of influenza viruses are
mainly determined using antisera isolated from ferrets recovering from primary influenza
infections. Unlike experimental ferrets, humans are typically reinfected with antigenically
distinct influenza strains throughout their life (Miller et al., 2013). In the 1950s, it was
noted that the human immune system preferentially mounts Ab responses that cross-react
to previously circulating influenza strains, at the expense of new Ab responses that
exclusively target newer viral strains (Davenport et al., 1953). This process, which
Thomas Francis, Jr. termed “original antigenic sin,” has been experimentally
recapitulated in ferrets (Li et al., 2013b; Webster, 1966), mice (Kim et al., 2009;
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Virelizier et al., 1974a; Virelizier et al., 1974b), and rabbits (Fazekas de St and Webster,
1966b). Our group and others recently demonstrated that the specificity of pH1N1 Ab
responses can be shaped by prior sH1N1 exposures (Carter et al., 2013; Li et al., 2012; Li
et al., 2013b; Pica et al., 2012; Wrammert et al., 2011). We found that ferrets sequentially
infected with sH1N1 and pH1N1 viruses mount Ab responses dominated against epitopes
that are conserved between the viral strains (Li et al., 2013b). These studies indicate that
sera collected from previously naïve ferrets infected a single time with influenza may not
be fully representative of human influenza immunity.
It has been proposed that increased morbidity and mortality of middle-aged adults
during the 2013-2014 influenza season was primarily a result of low vaccination rates
within these populations (Catania et al., 2014). An alternative explanation is that pH1N1
strains that circulated during that season had acquired a true antigenic mutation that was
mislabeled as “antigenically neutral” by assays that relied on sera collected from
previously naïve ferrets infected a single time with the 2009 pH1N1 virus. Here, we
completed a series of experiments to determine if pH1N1 strains that circulated during
the 2013-2014 influenza season possessed a mutation that prevented binding of Abs in
middle-aged humans who had been previously exposed to different sH1N1 strains.

RESULTS
Recent pH1N1 strains possess a mutation that prevents binding of human Abs
Antisera isolated from ferrets recovering from primary pH1N1 infections are
highly specific for an epitope involving HA residues 156, 157, and 158 of the Sa
antigenic site of H1 viruses (Chen et al., 2010b; Li et al., 2013b). Very few pH1N1
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isolates possessed mutations in these Sa residues as of 2014 (Fig. 6); however, pH1N1
viruses recently acquired a K166Q HA mutation, which is located at the interface of the
Sa/Ca antigenic sites (Caton et al., 1982) (Fig. 7A). The K166Q HA mutation first arose
during the 2012–2013 season and was present in over 99% of pH1N1 isolates during the
2013-2014 season (Fig. 7B-C). Based on experiments using antisera isolated from ferrets
infected for the first time, surveillance laboratories reported that pH1N1 viruses with the
K166Q HA mutation were antigenically indistinguishable from the A/California/07/2009
pH1N1 vaccine strain (Arriola et al., 2014).
To address if human Abs are capable of recognizing pH1N1 viruses with the
K166Q HA mutation, we performed hemagglutination inhibition (HAI) assays using sera
from healthy humans collected during the 2013–2014 influenza season in the United
States. Remarkably, 27% of sera from individuals born between 1940 and 1984 possessed
Abs specific for an epitope involving HA residue K166 (Fig. 8A and Table 9). Over 42%
of individuals born from 1965 to 1979 had K166 HA-specific Abs in their sera (n = 54
individuals). Sera isolated from individuals born between 1985 and 1997 (n = 49
individuals) did not have detectable levels of K166 HA-specific Abs. Differences in
K166 HA-specificity were statistically significant between sera isolated from individuals
born between 1965 and 1979 and individuals born after 1985 (Fisher’s exact test; P <
0.0001). Similar results were obtained when we analyzed sera from healthy humans
collected during the 2013–2014 influenza season in Mexico (Fig. 9 and Table 10).
It is remarkable that HAI assays, which are relatively insensitive, were able to
reproducibly detect K166 HA-specific Abs in so many individuals in our experiments.
Fig. 8A and Fig. 9 show percentages of donors that had at least a twofold reduction in
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HAI titer using the K166Q HA mutant virus in three independent assays. It is worth
pointing out that many sera samples had over fourfold reduced HAI titers using a pH1N1
virus engineered to possess the single K166Q HA mutation compared with the pH1N1
vaccine strain (Table 9). Age-related differences in K166 HA-specificity among United
States donors remained statistically significant using a fourfold reduction in HAI titer as a
cut-off (Fisher’s exact test; P < 0.05 comparing donors born between 1965 and 1979 and
donors born after 1985). Sera that had K166 HA-specificity based on HAI assays failed
to efficiently neutralize K166Q-possessing viruses in in vitro neutralization assays as
well (Table 11). K166 HA-specific sera were also unable to recognize a primary viral
isolate collected in 2013 (A/CHOP/1/2013) that possesses the K166Q HA mutation
(Table 11).

A glycosylation site present in sH1N1 viruses circulating after 1985 shields the K166
HA-epitope
Original antigenic sin Abs are originally primed by influenza strains that
circulated in the past (Davenport et al., 1953; Fazekas de St and Webster, 1966a, b; Li et
al., 2013b; Webster, 1966). We propose that K166 HA-specific Ab responses were likely
primed by sH1N1 viruses circulating in humans before 1985 and then boosted by the
2009 pH1N1 virus. Sera isolated from individuals born between 1965 and 1979 had the
highest K166 HA-specificity (both in percent and in titer) (Fig. 8A and Table 9). sH1N1
viruses that circulated in the late 1970s and early 1980s share extensive homology with
pH1N1 viruses in the vicinity of K166 (Fig. 8B). sH1N1 viruses were absent from the
human population from 1957 to 1976 and began infecting humans again in 1977.
70	
  

Therefore, humans born between 1957 and 1976 likely had their first H1N1 encounter
with a sH1N1 virus that shared homology with pH1N1 viruses in the vicinity of K166.
In 1986, sH1N1 viruses acquired a new glycosylation site at HA residue 129 that
is predicted to shield the epitope involving K166 (Figs. 10 and 11). The absence of K166
HA-specific Ab responses in individuals born after 1985 is likely because sH1N1 viruses
glycosylated at HA residue 129 fail to prime K166 HA-specific responses. The lower
number of K166 HA-specific responders born in the 1950s might also be attributed to
unique glycosylation sites in sH1N1 viruses that circulated during this time period (Fig.
10), although precise glycosylation statuses of viruses circulating before 1977 are
uncertain because of limited numbers of sequenced viruses. Although we did not examine
sera from very elderly individuals, it is possible that they also have immunodominant
K166 HA-specific responses, because a recent study reported that a mAb isolated from a
survivor of the 1918 H1N1 pandemic binds to pH1N1 in an epitope involving K166 (Xu
et al., 2010). There is considerable homology between the 1918 H1N1 virus and the 2009
pH1N1 virus in the vicinity of K166 (Xu et al., 2010).
To experimentally address if glycosylation sites present in previous sH1N1 strains
shield the epitope involving K166, we used reverse-genetics to produce pH1N1 viruses
that had glycosylation sites that were either present in sH1N1 strains from 1977-1985
(sites 131+163) or 1986-2008 (sites 129+163). Western blot analysis revealed that HA
residues 129 and 131, but not HA residue 163, were glycosylated in our reverse-genetics
derived viruses (Fig. 11B). Consistent with the hypothesis that the K166 HA-epitope is
shielded by glycosylation sites present in 1986-2008 sH1N1 viruses, K166 HA-specific
human sera had reduced titers to pH1N1 viruses with the 129-glycosylation site, but
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normal titers to pH1N1 viruses with the 131-glycosylation site (Fig. 11C). As a control,
we also completed HAI assays with sera from donors that were born in the 1970s who did
not have detectable levels of K166 HA-specific sera Abs. As expected, these sera did not
have reduced titers to pH1N1 viruses with the 129-glycosylation site, but interestingly,
these sera did have reduced titers to pH1N1 viruses with the 131-glycosylation site (Fig.
11C). We previously demonstrated that Ab responses focused on an epitope near the 131glycosylation site can be elicited by sequential infections with a sH1N1 virus from the
early 1990s and the pH1N1 virus (Li et al., 2013b). We speculate that donors in the “nonK166 HA-specific” group were previously infected with antigenically distinct sH1N1
strains compared with donors in the K166 HA-specific group (ie: A/Singapore/06/1986like strain instead of A/Chile/01/1983-like strain). Taken together, these data suggest that
glycosylation sites on previously circulating sH1N1 viruses shield epitopes and influence
the development of subsequent Ab responses against pH1N1 virus.

Vaccination with current pH1N1 vaccine strain elicits K166 HA-specific Abs
The pH1N1 vaccine strain has not been updated since 2009. We determined
whether this vaccine strain, which possesses an HA with K166, elicits K166 HA-specific
Abs in humans. First, we analyzed sera from individuals vaccinated in 2009. All of the
individuals in this cohort were born before 1984 and most did not have pH1N1 Ab titers
before vaccination (Table 12). Sera from 5 of 17 individuals possessed detectable levels
of K166 HA-specific Abs following vaccination (Fig. 12 and Table 12). Sera from all
five of these individuals had <1:40 HAI titers against the K166Q HA mutant pH1N1
virus (Table 12). One K166 HA-specific individual (subject #1) possessed K166 HA72	
  

specific Abs before vaccination (Fig. 12A and Table 12). It is possible that this individual
was naturally infected with pH1N1 before vaccination. All of the K166 HA-specific
donors had detectable pre-vaccination Ab titers against sH1N1 viruses from 1977 and
1983; however, we also found titers against these strains in some donors that did not have
detectable levels of K166 HA-specific serum Abs (Table 12). We also measured binding
of 42 HA head-specific monoclonal Abs (mAbs) isolated from 12 adult donors (born
1949-1985) that were vaccinated against the pH1N1 strain in 2009. Strikingly, 23% of
these mAbs had reduced binding to pH1N1 engineered to have the K166Q mutation (Fig.
12B). This finding is consistent with a previous report that identified several K166 HAspecific mAbs derived from a donor that was born before 1977 (Krause et al., 2011).
We passively transferred a K166 HA-specific mAb (SFV009-3F05) or a control
mAb that binds equally to WT and K166Q-HA pH1N1 viruses (SFV015-1F02) to
BALB/c mice 12 h before infecting them with a lethal dose of WT or K166Q-HA pH1N1
viruses. Control animals that did not receive a mAb before infection rapidly lost weight
and died or needed to be euthanized (Fig. 12C). Mice receiving the control SFV015-1F02
mAb before infection with WT or K166Q-HA pH1N1 viruses all survived with minimal
weight loss (Fig. 12C). Mice receiving the K166 HA-specific SFV009-3F05 mAb
survived following infection with WT pH1N1 but rapidly lost weight and died or needed
to be euthanized following infection with K166Q-HA pH1N1 (Fig. 12C). These data
suggest that K166 HA-specific Abs can be less efficient at preventing disease in a mouse
model following infection with a pH1N1 virus possessing K166Q HA.
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Can K166 HA-specific immunity be recapitulated in ferrets for surveillance purposes?
Current surveillance efforts rely heavily on antisera isolated from ferrets
recovering from primary influenza virus infections. Ferret antisera could potentially be
more reflective of human immunity if isolated from animals sequentially infected with
antigenically distinct viral strains. We attempted to elicit K166 HA-specific Abs in ferrets
by sequentially infecting animals with older sH1N1 strains and then the
A/California/07/2009 pH1N1 strain.
We initially infected animals with a sH1N1 virus that circulated in 1977
(A/USSR/90/1977), a sH1N1 virus that circulated in 1983 (A/Chile/01/1983), or a sH1N1
virus that circulated in 1986 (A/Singapore/06/1986). After 84 d, we re-infected animals
with the A/California/07/2009 pH1N1 strain. As controls, we infected some animals
twice with A/California/07/2009 and other animals only once with A/California/07/2009.
Three of eight ferrets sequentially infected with A/Chile/01/1983 and
A/California/07/2009 mounted K166 HA-specific Abs detectable in HAI assays (Fig. 13
and Table 13). The 22 ferrets in the other experimental groups did not mount detectable
levels of K166 HA-specific Abs. The difference in K166 HA-specificity is statistically
significant comparing the A/Chile/01/1983-A/California/07/2009 group with the rest of
the groups (3 of 8 vs. 0 of 22; Fisher’s exact test P < 0.05). K166 HA-specific Abs were
likely not elicited in the A/Singapore/06/1986-A/California/07/2009 group because the
K166 HA-epitope is predicted to be shielded by a glycosylation site at HA residue 129 of
A/Singapore/06/1986 (Fig. 11). It is interesting that K166 HA-specific Abs were not
elicited by A/USSR/90/1977-A/California/07/2009 sequential infections. This result is
likely because of variation at HA residue 125, which is close to HA residue 166 (Fig. 14).
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A/Chile/01/1983 and A/California/07/2009 both possess S125, whereas A/USSR/01/1977
possesses R125 (Fig. 14).

New pH1N1 vaccine strain candidate is antigenically distinct compared to
A/California/07/2009
Although the pH1N1 vaccine strain component has not been updated since 2009,
a new strain was added to the list of “A/California/07/2009-like” candidate strains for the
upcoming 2016-2017 influenza season (Anonymous, 2016). Despite being labeled as
antigenically identical to the A/California/07/2009 vaccine strain, the new strain, A/South
Africa/3626/2013, possesses the HA K166Q mutation compared to the current vaccine
strain. This is the first virus added to list of H1N1 candidate vaccine strains that possesses
a glutamine at HA residue 166. Based on our previous data indicating that a large
percentage of middle-aged adult human sera possess Abs that are sensitive to the HA
K166Q mutation, we hypothesized that A/South Africa/3626/2013 is actually an
antigenically distinct virus compared to A/California/07/2009. We generated both the
A/California/07/2009 X-179A (Cal X-179A) and A/South Africa/3626/2013 X-243 (S.A.
X-243) vaccine strains using reverse genetics and PR8 internals. After rescue, the viruses
were expanded in eggs similar to how the vaccine strains are produced.
We then performed HAI assays using antisera collected from middle-aged adults
(born 1977-1985), both before (d0) and after (d21) vaccination with
A/California/07/2009, during the 2013-2014 influenza season (Fig. 15). Even before
vaccination, the majority of the 20 individuals from the cohort had anti-pH1N1 Ab titers.
Of the 14 samples with titers against Cal X-179A, 36% had HAI titers reduced at least
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twofold against S.A. X-243 (Fig. 15A). Following vaccination, the percentage of
individuals with at least a twofold reduction in HAI titer against S.A. X-243 was 37%
(Fig. 15B). These results are consistent with data from Fig. 8A, where the sera from 42%
of the middle-aged adults (born 1965-1979) in our cohort had reduced HAI titers against
a virus containing the K166Q HA mutation. Relative receptor binding avidities of the two
viruses were calculated to have no significant difference (Fig. 15C), indicating that
observed changes in HAI titers were likely due to antigenic differences.
Overall, the HAI data confirms our hypothesis that A/South Africa/3626/2013 is
an antigenically distinct strain and should not be labeled as antigenically identical to the
current A/California/07/2009 vaccine strain. This is important because vaccine
preparations including Cal X-179A as the H1N1 component could produce different
immunogenic responses than those vaccines including S.A. X-243 as the H1N1
component. Middle-aged adults would likely benefit more from receiving a vaccine with
the more recent S.A. X-243 vaccine strain because it does not include an intact K166
HA-epitope and thus would presumably not elicit the K166 HA-specific Ab response that
leaves them more susceptible to infection with current pH1N1 strains.

DISCUSSION
Our studies show that pH1N1 viruses that circulated during the 2013-2014
influenza season acquired a significant antigenic mutation that prevents binding of Abs
elicited in a large number of middle-aged humans. For this reason, we propose that the
pH1N1 vaccine strain should be updated. Conventional serological techniques used by
most surveillance laboratories failed to recognize the K166Q HA mutation as
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antigenically important (Arriola et al., 2014). HAI assays are based on serial sera
dilutions and can only detect large antigenic changes. Many surveillance-based
laboratories ignore twofold reductions in HAI titer because these laboratories typically
process thousands of samples, which prohibit the experimental precision that is required
to reliably detect twofold differences in these assays. However, a true twofold reduction
in HAI titer against a mutated strain indicates an extremely immunodominant Ab
response. Although we reproducibly detected as low as twofold HAI differences using
K166Q HA mutated viruses (Tables 9 and 10 show results from three independent HAI
experiments), our HAI assays likely underestimate the number of individuals that possess
K166 HA-specific Abs. For example, we were able to isolate K166 HA-specific mAbs
from pH1N1-vaccinated individuals whose sera yielded similar HAI titers using WT and
K166Q mutated pH1N1 viruses. We also identified many human sera samples that had
>fourfold reductions in HAI titer using pH1N1 viruses with the K166Q HA mutation,
and it is worth noting that these results would likely have been missed if we pooled
human sera samples or simply compared overall geometric means of HAI data with
mutant viruses.
We attempted to recapitulate K166 HA-specific immunity in ferrets by
sequentially infecting with sH1N1 strains and the A/California/07/2009 pH1N1 strain.
Only three of eight ferrets sequentially infected with A/Chile/01/1983 and
A/California/07/2009 mounted levels of K166 HA-specific Abs that could be detected by
HAI assays. Outbred ferrets were used in these experiments, and the overall percentage
of ferrets with K166 HA-specificity (Fig. 13) is similar to the overall percentage of
humans born in the 1970s with K166 HA-specificity (Fig. 8A). We speculate that
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variation in K166 HA-specificity in humans is due to variations in pre-exposure histories
and genetic differences that impact B-cell repertoires.
Our results offer a possible antigenic explanation for the increased disease burden
observed in middle-aged adults during the 2013–2014 influenza season. Given that the
specificity of Ab responses is altered by pre-exposure history, we propose that
conventional serological techniques used to identify antigenically novel viruses should be
reevaluated. The usefulness of arbitrary HAI titer cutoffs and dependence on antisera
generated in previously naïve ferrets (Koel et al., 2013; Smith et al., 2004) should be
reconsidered. Although we believe that the pH1N1 vaccine should be updated
immediately to a more recent strain (one that possesses HA Q166, similar to A/South
Africa/3626/2013), it is not clear if a pH1N1 vaccine strain with Q166 HA will be able to
break the original antigenic sin that currently exists in some middle-aged individuals.
Further studies should be designed to determine if an updated H1N1 vaccine strain with
Q166 HA elicits more effective Ab responses in different aged humans with distinct
sH1N1 exposure histories.

MATERIALS AND METHODS
Human Donors
Studies involving human adults were approved by the Institutional Review Boards
of Emory University, Vaccine and Gene Therapy Institute of Florida, the National
Institute of Respiratory Diseases of Mexico, and the Wistar Institute. Informed consent
was obtained. For all experiments, HAI and in vitro neutralization assays were completed
at the Wistar Institute using preexisting and de-identified sera. We analyzed several sera
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panels in this study. We analyzed sera from healthy donors collected at the New York
Blood Center in February of 2014. We analyzed sera from healthy donors collected at the
Center for Research in Infectious Diseases at the National Institute of Respiratory
Diseases in Mexico. We analyzed sera and mAbs derived from healthy donors vaccinated
with a monovalent pH1N1 vaccine in 2009 as previously described (Li et al., 2012). We
analyzed sera collected from middle-aged adults (born 1977-1985) vaccinated with
A/California/7/2009 at the Vaccine and Gene Therapy Institute of Florida (VGTI) during
the 2013-2014 influenza season.

Viruses
Viruses possessing WT pH1N1 HA or K166Q pH1N1 HA were generated via
reverse-genetics using HA and NA genes from A/California/07/2009 and internal genes
from PR8. All of these viruses were engineered to possess the antigenically neutral
D225G HA mutation (Chen et al., 2010a), which facilitates viral growth in fertilized
chicken eggs. Viruses were grown in fertilized chicken eggs and the HA genes of each
virus stock were sequenced to verify that additional mutations did not arise during
propagation. sH1N1 strains (A/USSR/90/1977, A/Chile/01/1983, A/Singapore/06/1986,
A/Texas/36/1991, A/New Caledonia/20/1999, and A/Solomon Islands/03/2006) were
also grown in fertilized chicken eggs. We isolated a pH1N1 virus from respiratory
secretions obtained from a patient from the Children’s Hospital of Philadelphia in 2013
(named A/CHOP/1/2013 in this report). For this process, de-identified clinical material
from the Children’s Hospital of Philadelphia Clinical Virology Laboratory was added to
Madin-Darby canine kidney (MDCK) cells (originally obtained from the National
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Institutes of Health) in serum-free media with L-(tosylamido-2-phenyl) ethyl
chloromethyl ketone (TPCK)-treated trypsin, HEPES, and gentamicin. Virus was isolated
from the MDCK-infected cells 3 d later. We extracted viral RNA and sequenced the HA
gene of A/CHOP/1/2013. We also used reverse-genetics to introduce glycosylation sites
into A/California/07/2009 (pH1N1) HA. The consensus sequence for N-linked
glycosylation (N-x-S/T) was added at HA residues 129, 131, and 163 by making the
mutations D131T, D131N and N133T, and K163N, respectively. Similar results were
obtained in HAI assays when we used glycosylation mutants grown in eggs or MDCK
cells. Glycosylation at HA residues 129 and 131 was confirmed by treating concentrated
virus with PNGase-F (New England Biolabs) under denaturing conditions. The CM1-4
anti-HA1 antibody was used as a primary antibody, and a donkey anti-mouse fluorescent
secondary antibody (Licor) was used. Blots were imaged using the Licor Odyssey
imaging system at 800nm (secondary antibody) and 700 nm (molecular weight marker).

Candidate Vaccine Strains
The HA genes of A/California/7/2009 WT and A/CHOP/1/2013 WT were cloned
into the reverse genetics vector pHW2000. Site-directed mutagenesis was then used to
generate both the A/California/7/2009 X-179A (Cal X-179A) and A/South
Africa/3626/2013 X-243 (S.A. X-243) egg-adapted vaccine strain HA gene sequences.
K212T and Q226R were inserted into the A/California/7/2009 WT HA to generate Cal
X-179A HA. Likewise, D131E and L697V were inserted into the A/CHOP/1/2013 WT
HA to generate S.A. X-243 HA. Reverse genetics were then used to rescue virus by
transfecting a co-culture of 293T and MDCK cells with the Cal X-179A or S.A. X-243
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HA genes along with the neuraminidase (NA) gene from A/California/07/2009 and the
six internal influenza genes from PR8. Rescued virus was expanded in eggs one time and
then sequence confirmed.

Animal Experiments
Murine experiments were performed at the Wistar Institute according to protocols
approved by the Wistar Institute Institutional Animal Care and Use Committee. BALB/c
mice (Charles River Laboratories) were injected with 25 µg of mAb intraperitoneally and
then infected intranasally with 20,000 TCID50 of WT or K166Q-HA pH1N1 virus 12 h
later. As controls, some mice received an intraperitoneal injection of PBS before
infection. Weight loss and survival was recorded for 11 days. Severely sick mice were
euthanized. Ferret experiments were performed at VGTI in accordance with the National
Research Council’s Guide for the Care and Use of Laboratory Animals, the Animal
Welfare Act, and the CDC/NIH Biosafety in Microbiological and Biomedical
Laboratories handbook. Fitch ferrets (Marshall Farms) were infected with 1×106 PFU of
sH1N1 virus and bled 14 and 84 d later. These ferrets were then infected with the
A/California/07/2009 pH1N1 strain and bled 14 d later. Some ferrets were sequentially
infected with A/California/07/2009 (84 d between infections) and other ferrets were
infected with A/California/07/2009 only once and bled 14 d later.

HAI Assays
Sera samples were pretreated with receptor-destroying enzyme (RDE, Key
Scientific Products or Sigma-Aldrich) and HAI titrations were performed in 96-well
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round-bottom plates (BD). Sera were serially diluted twofold and added to four
agglutinating doses of virus in a total volume of 100 µL. Turkey red blood cells (RBCs,
Lampire) were added [12.5 µL of a 2% (vol/vol) solution]. The RBCs were gently mixed
with sera and virus and agglutination was read out after incubating for 60 min at room
temperature. HAI titers were expressed as the inverse of the highest dilution that inhibited
four agglutinating doses of turkey RBCs. Each HAI assay was performed independently
on three different dates. Sera that had at least twofold reduced HAI titers using K166Q
HA mutant viruses in three independent HAI assays were labeled as “K166 HA-specific.”
For the HAI assays to compare the vaccine strains, sera that had at least a twofold
reduction in HAI titer against S.A. X-243 in three separate experiments were counted as
specific for Cal X-179A.

ELISA Assays
Viruses for ELISAs were concentrated by centrifugation at 20,000 RPM for 1 h
using a Thermo Scientific Sorvall WX Ultra 80 Centrifuge with a Beckman SW28 rotor.
Concentrated viruses were then inactivated by beta-propiolactone (BPL; Sigma Aldrich)
treatment. Viruses were incubated with 0.1% BPL and 0.1M HEPES (Cellgro) overnight
at 4°C followed by a 90 min incubation at 37 °C. The 96-well Immulon 4HBX flatbottom microtiter plates (Fisher Scientific) were coated with 20 HAU of BPL-treated
virus per well overnight at 4°C. Each human mAb was serially diluted in PBS and added
to the ELISA plates and allowed to incubate for 2 h at room temperature. As a control,
we added the 70-1C04 stalk-specific mAb to verify equal coating of WT and K166Q HA
virus. Next, peroxidase-conjugated goat anti-human IgG (Jackson Immunoresearch) was
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incubated for 1 h at room temperature. Finally, SureBlue TMB Peroxidase Substrate
(KPL) was added to each well and the reaction was stopped with addition of 250 mM
HCl solution. Plates were extensively washed with distilled water between each ELISA
step. Affinities were determined by nonlinear regression analysis of curves of six mAb
dilutions (18 µg/mL to 74 ng/mL) using Graphpad Prism. mAbs were designated as K166
HA-specific if they had a Kd at least four times greater for the K166Q mutant than for the
WT virus.

In Vitro Neutralization Assays
Sera were serially diluted twofold and then added to 100 TCID50 units of virus
and incubated at room temperature for 30 min. The virus-sera mixtures were then
incubated with MDCK cells for 1 h at 37°C. Cells were washed and then serum-free
media with TPCK-treated trypsin, HEPES, and gentamicin was added. Endpoints were
determined visually 3 d later. Data are expressed as the inverse of the highest dilution that
caused neutralization. All samples were repeated in quadruplicate and geometric mean
titer is reported.

Receptor Binding Avidity Assays
Turkey RBCs (Lampire) were pretreated with various concentrations of α2-3,6,8
neuraminidase (NEB) for 60 min at 37°C. The treated RBCs were washed two times with
PBS and added (as 1% v/v solutions) to eight agglutinating does of each virus
(determined using non-treated turkey RBCs). Hemagglutination was measured after 60
min and receptor binding avidities were reported as the maximum concentration of
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neuraminidase (units/mL) that still allows for full hemagglutination. Assay was
completed three independent times.

Structural Modeling of HA Glycosylation Sites
Glycans were modeled onto positions 129 and 131 in the A/Solomon
Islands/03/2006 HA crystal structure (PDB entry 3SM5) using the GLYCAM Web
Glycoprotein Builder (www.glycam.org). The particular glycan used for modeling was an
N-linked glycan with a trimannosyl core (DManpa1-6[DGlcpNAcb1-2DManpa13]DManpb1-4DGlcpNAcb1- 4DGlcpNAcb1-OH in Glycam notation), and default
rotamer settings were used for modeling. To model the 131-glycosylation site, a T131N
mutation was introduced using the PyMol structure viewer before the structure was
uploaded to the GLYCAM-Web server.

Computational and Phylogenetic Analyses of HA Sequences
The occurrence of different amino acid identities at HA residues 166, 156, 157,
and 158 (H3 numbering) was analyzed by downloading all full-length human pH1N1
sequences present in the Influenza Virus Resource (Bao et al., 2008) as of February 23,
2014. After purging sequences that were less than full-length, contained ambiguous
nucleotide identities, lacked full (year, month, day) isolation dates, or were otherwise
anomalous, the sequences were aligned. Each calendar year was broken into four equal
partitions beginning with January 1, and the frequencies of different amino acids at each
residue of interest for each partition was calculated and plotted. Only amino acids that
reached a frequency of at least 1% in at least one of the year partitions are labeled in the
84	
  

legend to the plot. For construction of phylogenetic trees, the sequence set was randomly
subsampled to 10 sequences per quarter-year partition. BEAST (Drummond et al., 2012)
was then used to sample from the posterior distribution of phylogenetic trees with
reconstructed sequences at the nodes, after date stamping the sequences, using a Jones,
Taylor, and Thornton (JTT) matrix (Jones et al., 1992) with a single rate category with an
exponential prior, a strict molecular clock, and relatively uninformative coalescent-based
prior over the tree. Fig. 7C shows a maximum clade credibility summary of the posterior
distribution with branches colored according to the reconstructed amino acid identity at
HA residue 166 with the highest posterior probability at their descendent nodes. The tree
was visually rendered using FigTree. The input data and computer code used for this
analysis can be found on GitHub at github.com/jbloom/pdmH1N1_
HA_K166_mutations.

Statistical Analyses
For all serum experiments, we excluded samples that did not have positive
pH1N1 HAI titers. All samples that were pH1N1 HA-WT HAI-negative were also
pH1N1 HA-K166Q HAI-negative. Samples were allocated to specific groups based on
age of donor. The year of birth of each sample was available during the experiment, but
this information was not assessed until after each experiment was completed. Variance of
raw HAI titers was similar between different age groups. Fisher’s exact tests were
completed using SAS v9.3 software. For the receptor binding avidity assay, mean and
standard error were calculated. A paired, two-tailed t-test was performed using SAS v9.3
software to determine significance.
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Figure 6. Sequence variation of pH1N1 HA.

The residues in the dominant antigenic site recognized by Abs elicited in previously
naïve ferrets infected once with the A/California/07/2009 WT vaccine strain (HA
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residues 156, 157, and 158 of the Sa antigenic site) are highly conserved in recent pH1N1
viruses (A–C). No variation greater than 1% has occurred at HA residue 156 and very
little variation has occurred at HA residues 157 and 158. For comparison, HA residue 166
(D; also shown in Fig. 7B) underwent a complete change during the 2013-2014 influenza
season.
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from the A/California/7/2009 pH1N1 vaccine strain (9).
To address if human Abs are capable of recognizing pH1N1
viruses with the K166Q HA mutation, we performed hemagglutination-inhibition (HAI) assays using sera from healthy
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possessed K166 from 2009 to mid-2012, but most isolates possessed Q166 by the 2013–
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2014 season. (C) A phylogenetic tree of pH1N1 viruses with branches colored according
to amino acid identity at residue 166 illustrates the rapid fixation of K166Q in pH1N1
isolates that circulated in 2013.
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% Specific to antigenic site
involving K166

A
A
50

donors from United States
*
23/54 K166-specific

40
30
20

0/49 K166-specific

10

19
19401945-44
1950-49
1955-54
1960-59
1965-64
1970-69
1975-74
1980-79
1985-84
1990-89
95 94
-9
7

0

Year born

B
B
166

Homology between
A/Chile/01/1983 and
A/California/07/2009
Fig. 2. Adult humans possess Abs that bind to a region of HA that was
89	
  
recently mutated in pH1N1. (A) Sera were isolated from healthy donors (n =
195) from the state of New York during the 2013–2014 influenza season. HAI
assays were performed using viruses with either WT A/California/07/2009 HA
or A/California/07/2009 HA with a K166Q HA mutation. For each sera sample,
we completed three independent HAI assays. Raw HAI data are reported in
Table S1. Percentages of samples that had at least a twofold reduction in HAI
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Figure 8. Middle-aged adults possess Abs that bind to a region of HA that became
mutated in pH1N1 viruses during the 2013-2014 influenza season.
(A) Sera were isolated from healthy donors (n = 195) from the state of New York during
the 2013–2014 influenza season. HAI assays were performed using viruses with either
WT A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation.
For each sera sample, we completed three independent HAI assays. Raw HAI data are
reported in Table 9. Percentages of samples that had at least a twofold reduction in HAI
titer against the mutant virus in three independent experiments are shown. K166 HAspecificity of sera from individuals born between 1965 and 1979 is statistically
significant compared with K166 HA-specificity of sera from individuals born after 1985
(Fisher’s exact test; *P < 0.0001). (B) Homology between the A/Chile/01/1983 sH1 and
the A/California/04/2009 pH1 are shown using the crystal structure of the
A/California/04/2009 HA [PDB entry 3UBN (Xu et al., 2010)]. Residue K166 is colored
green. Amino acids that differ between A/Chile/01/1983 and A/California/04/2009 are
shown in red. The glycan receptor is shown in black.
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131 only
165 only
131+165

131 only
163 only
129+158+163
131+158+163
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131+163

129+163

none

Year born

Fig. S2. Mexican donors born before 1985 possess Abs that bind to the region of HA that was recently mutated in pH1N1. Sera were isolated from he
donors (n = 45) at the Center for Research in Infectious Diseases at the National Institute of Respiratory Diseases in Mexico during the 2013–2014 influ
season. HAI assays were performed using viruses with either WT A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation. For each
sample, we completed three independent HAI assays. Raw HAI data are reported in Table S2. Percentages of samples that had at least a twofold reducti
Figure
HAI titer using the mutant
virus in10
three independent experiments are shown. (Fisher’s exact test; *P < 0.05).
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Fig. S3. Glycosylation status of H1N1 viruses. The crystal structures of sH1N1 (A) and pH1N1 (B) HAs are shown (PDB ID codes 3SM5 and 3UBN). Glycosyl
sites that have appeared from 1918 to 2008 in sH1N1 viruses are highlighted in orange and residue 166 is shown in green. (C) Glycosylation status of H
viruses circulating during different time periods is shown as reported in Wei et al. (1). Very few viral sequences are available for 1930–1950 viruses
10. Glycosylation
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viruses.
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viruses likely relates
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adaptations.
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Sa/Sb ridge.
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of sH1N1
(A)located
and pH1N1
(B) sides
HAsofare
(PDB
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cover the K166 epitope, whereas the 129 glycosylation site potentially shields the K166 epitope.

and 3UBN). Glycosylation sites that have appeared from 1918 to 2008 in sH1N1 viruses
1. Wei CJ, et al. (2010) Cross-neutralization of 1918 and 2009 influenza viruses: Role of glycans in viral evolution and vaccine design. Sci Transl Med 2(24):24ra21.

are highlighted in orange and residue 166 is shown in green. (C) Glycosylation status of
H1N1 viruses circulating during different time periods is shown as reported previously
(Wei et al., 2010). Very few viral sequences are available for 1930–1950 viruses and
variability of glycosylation sites in these viruses likely relates to egg adaptations. The
Linderman et al. www.pnas.org/cgi/content/short/1409171111
majority of sH1N1 viruses

circulating between 1977 and 1985 have the 131- and 163-

glycosylation sites and the majority of sH1N1 viruses circulating between 1986 and 2008
have the 129- and 163-glycosylation sites. Of note, although HA residues 129 and 131
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3

are very close in the linear sequence, they are located on opposite sides of the Sa/Sb
ridge. The 131-glycosylation site is not expected to cover the K166 HA-epitope, whereas
the 129-glycosylation site potentially shields the K166 HA-epitope.
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Fig. S4. Modeling 129 and 131 glycosylation sites. (A) Modeling of the putative glycosylation sites at residues 129 and 131 on the HA of A/Solomon Island
2006 (PDB ID code 3SM5) was completed using Glycam software (Materials and Methods). Residues 129 and 131 are shown in orange and predicted sug
are shown in black. Residue 166 is shown in green. The 129 glycosylation site present in most sH1N1 isolates circulating after 1985 is predicted to sh
the antigenic site involving residue 166. The 131 glycosylation site is not predicted to shield the antigenic site involving residue 166. (B) Viruses possess
A/California/07/2009 HA with different putative glycosylation sites were created by reverse-genetics. HA from viruses with putative glycosylation sites introdu
at residues 129+163 and 131+163 migrated slower compared with unmodified HA and HA from viruses with a putative glycosylation site at only residue 1
Figure 11. Modeling glycosylation sites at HA residues 129 and 131.
This finding indicates that residues 129 and 131, but not residue 163 was glycosylated in the reverse-genetics derived viruses. HA from all viruses migra
similarily following PNGase treatment. PNGase treatment was completed under reducing conditions, so HA migrated faster compared with no PNG
treatment. (C) HAI (A)
assays
were completed
the reverse-genetics
derived
possessing
A/California/07/2009
different
Modeling
of theusing
putative
glycosylation
sitesviruses
at residues
129
and 131 on thewith
HA
of glycosylation sites. F
K166 HA-specific samples and five non-K166 HA-specific human samples were tested.

A/Solomon Islands/6/ 2006 (PDB entry 3SM5) was completed using Glycam software.
HA residues 129 and 131 are shown in orange and predicted sugars are shown in black.
HA residue 166 is shown in green. The 129-glycosylation site present in most sH1N1
125

166
isolates circulating after 1985 is predicted
to shield the antigenic epitope involving HA

residue 166. The 131-glycosylation site is not predicted to shield the antigenic epitope
involving HA residue 166. (B) Viruses possessing A/California/07/2009 HA with
different putative glycosylation sites were created by reverse-genetics. HA from viruses
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Fig. S5. Homology betwen A/USSR/90/1977, A/Chile/01/1983, and A/California/07/2009. HA residues that differ between A/Chile/01/1983 and the A/Califor
07/2009 are shown in red. A few additional HA residues differ between the HAs of A/USSR/90/1977 and A/California/7/2009, and these are colored yellow

with putative glycosylation sites introduced at HA residues 129+163 and 131+163
migrated slower compared with unmodified HA and HA from viruses with a putative
glycosylation site at only HA residue 163. This finding indicates that HA residues 129
and 131, but not HA residue 163, were glycosylated in the reverse-genetics derived
viruses. HA from all viruses migrates similarly following PNGase treatment. PNGase
treatment was completed under reducing conditions, so HA migrated faster compared
with no PNGase treatment. (C) HAI assays were completed using the reverse-genetics
derived viruses possessing A/California/07/2009 with different glycosylation sites. Five
K166 HA-specific samples and five non-K166 HA-specific human samples were tested.
Data are representative of three independent experiments.
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Figure 12.
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Fig. 3. Vaccination of middle-aged adults with the current pH1N1 vaccine strain elicits Abs that bind to a region of HA that is now mutated in most pH1N1
isolates. (A) Healthy adult volunteers were vaccinated with a monovalent pH1N1 vaccine in 2009. Sera were isolated prevaccination and 30 d postvaccination
and HAI assays were performed using viruses with either WT A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation. Shown are HAI
titers for donors that possessed K166 HA-specific Abs following vaccination. Data are representative of three independent experiments. Raw HAI titers for all
donors are shown in Table S4. (B) ELISAs were completed using mAbs isolated from healthy adult volunteers that were vaccinated with a monovalent pH1N1
vaccine in 2009. ELISAs were coated either with A/California/07/2009 (WT) or A/California/07/2009 with a K166Q HA mutation. Shown are percentage of mAbs
that bound to both viruses and percentage of mAbs that bound to the WT virus but not the mutant virus (n = 42 mAbs). Data are representative of two
independent experiments. (C) A K166 HA-specific mAb (SFV009-3F05) or a mAb that recognizes both WT and K166Q-HA pH1N1 (SFV015-1F02) were injected
into BALB/c mice (n = 4 per group). Twelve hours later, mice were then infected with 20,000 TCID50 of WT or K166Q-HA virus and weight loss and survival
were recorded for 11 d. Data are representative of two independent experiments.

Figure 12. Vaccination of middle-aged adults with the current pH1N1 vaccine strain
elicits Abs that bind to a region of HA that is now mutated in most pH1N1 isolates.
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vaccinated
a monovalent
in 2009.
Conventional
serological pH1N1
techniquesvaccine
used by most
surveillance
sequentially
infecting
animals
with older sH1N1
and then with

the WT virus but not the K166Q mutant virus (n = 42 mAbs). Data are representative of
two independent experiments. (C) A K166 HA-specific mAb (SFV009-3F05) or a mAb
that recognizes both WT and K166Q-HA pH1N1 (SFV015-1F02) were injected into
BALB/c mice (n = 4 per group). Twelve hours later, mice were then infected with 20,000
TCID50 of WT or K166Q-HA virus and weight loss and survival were recorded for 11 d.
Data are representative of two independent experiments.
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red. A few additional HA residues differ between the HAs of A/USSR/90/1977 and
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Figure 15
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Figure 15. Vaccinated human sera demonstrate the new candidate H1N1 vaccine
strain, A/South Africa/3626/2013, is antigenically distinct from
A/California/07/2009.
Sera were collected from vaccinated middle-aged adults (born 1977-1985) during the
2013-2014 influenza season at the Vaccine and Gene Therapy Institute of Florida (n =
20). Both (A) pre- and (B) post-vaccination HAI titers were determined against the Cal
X-179A and S.A. X-243 vaccine strains. Displayed is the fraction of individuals who had
titers against Cal X-179A and at least a twofold decrease in HAI titer against S.A. X-243
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in three independent experiments. (C) Relative binding avidity between the two viruses
was determined by pre-treating turkey RBCs with different dilutions of α2-3,6,8
neuraminidase before measuring hemagglutination. Neuraminidase concentration is
reported as the maximum units/mL of neuraminidase that still allows for full
hemagglutination. Mean and standard error bars are shown. The difference in receptor
binding avidity between Cal X-179A and S.A. X-243 is insignificant following three
independent assays (p=0.0535, paired two-tailed t-test).
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TableTable
9 S1.

HAI titers using sera from healthy donors from the United States
Exp. 1
HAI titers

Exp. 2
Ratio

HAI titers

Exp. 3
Ratio

HAI titers

Ratio

Sample ID

YOB

WT

K166Q

WT/K166Q

WT

K166Q

WT/K166Q

WT

K166Q

WT/K166Q

40–60
40–49
40–05
40–02
40–44
40–14
40–16
50–55
50–11
50–43
50–06
60–04
60–10
60–13
60–25
60–14
60–23
60–44
60–28
60–41
60–63
60–35
70–56
70–52
70–60
70–74
70–36
70–84
70–86
70–13
70–54
70–25
70–10
70–23
70–82
70–50
70–80
70–19
80–16
80–48

1940
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1948
1948
1949
1949
1952
1952
1953
1959
1963
1963
1964
1964
1967
1967
1968
1969
1969
1969
1969
1971
1971
1972
1972
1972
1973
1973
1975
1975
1975
1975
1975
1976
1976
1978
1978
1980
1983

160
80
160
120
320
240
240
160
120
80
120
80
160
240
60
160
320
160
320
120
120
80
80
160
160
160
240
120
160
640
160
160
160
160
160
240
320
80
80
640

80
<20
80
60
80
80
<20
80
40
40
60
40
80
120
20
80
120
80
160
60
60
40
40
<20
80
80
60
40
40
320
80
80
30
<20
80
80
160
<20
30
120

2.00
>4.00
2.00
2.00
4.00
3.00
>12.00
2.00
3.00
2.00
2.00
2.00
2.00
2.00
3.00
2.00
2.67
2.00
2.00
2.00
2.00
2.00
2.00
>8.00
2.00
2.00
4.00
3.00
4.00
2.00
2.00
2.00
5.33
>8.00
2.00
3.00
2.00
>4.00
2.67
5.33

160
60
160
60
320
240
160
160
80
80
80
80
240
320
80
120
320
160
320
160
120
80
80
120
160
240
240
160
160
640
80
80
80
120
160
160
320
80
60
640

80
<20
80
30
80
80
<20
60
30
40
40
40
80
120
30
60
160
80
160
80
60
30
30
<20
80
80
30
30
30
320
30
30
30
<20
60
60
160
<20
20
80

2.00
>3.00
2.00
2.00
4.00
3.00
>8.00
2.67
2.67
2.00
2.00
2.00
3.00
2.67
2.67
2.00
2.00
2.00
2.00
2.00
2.00
2.67
2.67
>6.00
2.00
3.00
8.00
5.33
5.33
2.00
2.67
2.67
2.67
>6.00
2.67
2.67
2.00
>4.00
3.00
8.00

160
80
160
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320
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160
160
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80
80
80
160
240
60
120
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160
320
160
120
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80
80
160
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320
160
160
640
120
120
80
160
160
120
320
80
80
640

60
<20
80
30
80
80
<20
80
30
40
30
40
60
120
20
60
160
80
160
80
60
30
40
<20
80
80
30
40
40
320
60
40
30
<20
80
60
160
<20
40
80

2.67
>4.00
2.00
2.67
4.00
3.00
>8.00
2.00
2.67
2.00
2.67
2.00
2.67
2.00
3.00
2.00
2.00
2.00
2.00
2.00
2.00
2.67
2.00
>4.00
2.00
3.00
10.67
4.00
4.00
2.00
2.00
3.00
2.67
>8.00
2.00
2.00
2.00
>4.00
2.00
8.00

Sera were isolated from 195 healthy donors from the state of New York during the 2013–2014 influenza
season. HAI assays were performed using viruses with either WT A/California/07/2009 HA or A/California/07/2009
HA with a K166Q HA mutation. For each sera sample, we completed three independent HAI assays. Shown are
samples that had at least a twofold reduction in HAI titer using the mutant virus in three independent experiments. YOB, year of birth.

Table 9. HAI titers using sera collected from healthy human donors from the United
States.
Sera were isolated from 195 healthy donors from the state of New York during the 20132014 influenza season. HAI assays were performed using viruses with either WT
A/California/07/2009 HA or A/California/07/2009 HA with a K166Q HA mutation. For
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each sera sample, we completed three independent HAI assays. Shown are samples that
had at least a twofold reduction in HAI titer using the K166Q mutant virus in all three
independent experiments. YOB, year of birth.
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Table 10
Table S2. HAI titers using sera from healthy donors from Mexico
Exp. 1
HAI titers

Exp. 2
Ratio

HAI titers

Exp. 3
Ratio

HAI titers

Ratio

Sample ID

YOB

WT

K166Q

WT/K166Q

WT

K166Q

WT/K166Q

WT

K166Q

WT/K166Q

N-33
N-42
N-93
N-72
N-70

1973
1975
1977
1979
1980

160
40
120
30
160

60
<10
30
<10
80

2.67
>4.00
4.00
>3.00
2.00

120
30
60
30
120

40
<10
30
<10
60

3.00
>3.00
2.00
>3.00
2.00

80
30
60
20
120

30
<10
20
<10
40

2.67
>3.00
3.00
>2.00
3.00

Sera were isolated from 45 healthy donors from Mexico during the 2013–2014 influenza season. HAI assays
were performed using viruses with either WT A/California/07/2009 HA or A/California/07/2009 HA with a K166Q
HA mutation. For each sera sample, we completed three independent HAI assays. Shown are samples that had at
least a10.
twofold
in HAI titer
using
the mutant
virus in
three independent
experiments.
Table
HAIreduction
titers using
sera
collected
from
healthy
human donors
from Mexico.

Sera were isolated from 45 healthy donors from Mexico during the 2013-2014 influenza
Table S3. Characterization of K166 HA-specific sera

HAI titersusing viruses with either
In vitro
neutralization
titers
season. HAI assays were performed
WT
A/California/07/2009
Sample ID

YOB

A/CAL/07/09-WT HA A/CHOP/1/2013 A/CAL/07/09-WT HA A/CAL/07/09-K166Q HA

HA or A/California/07/2009 HA with a K166Q HA mutation. For each sera sample, we
40–49
1943
20
<10
24
12
40–44
1948
160
30
453
95
completed
three
Shown are samples
a
40–16
1949 independent
80 HAI assays.
<10
160 that had at least20
70–52
1971
40
<10
190
28
70–36
120 the K166Q mutant
10
reduction
in1972
HAI titer using
virus in all381three independent 95
70–84
1973
40
<10
160
57
70–86
1973
60
20
190
67
experiments.
70–23
1975
80
<10
226
20
70–19
1978
30
<10
95
10
80–48
1983
320
30
1,076
80
80–10
1986
160
160
761
1,810
80–26
1986
80
80
113
160
80–74
1986
40
40
135
113
80–30
1987
20
10
67
113
80–34
1987
160
160
381
538
80–56
1988
20
<10
17
34
90–01
1990
40
10
48
80
90–24
1991
60
20
34
95
90–12
1992
160
60
190
226
90–13
1992
80
80
190
320

twofold

We further characterized several sera samples that had immunodominant K166 HA-specific Abs (light gray:
K166 HA-specific sera from individuals born before 1985; darker gray: sera from individuals born after 1985). HAI
assays were completed using viruses with the A/California/07/2009 HA-WT and a primary pH1N1 virus isolated
from the Children’s Hospital of Philadelphia (CHOP) in 2013. Additional in vitro neutralization assays were
completed using the reverse-genetics derived viruses. Data are representative of two independent experiments.
For each neutralization assay, each sample was titered four times, and geometric mean of these quadruplicate
samples is reported.
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N-70

1980

160

80

2.00

120

60

2.00

120

40

3.00

Sera were isolated from 45 healthy donors from Mexico during the 2013–2014 influenza season. HAI assays
were performed using viruses with either WT A/California/07/2009 HA or A/California/07/2009 HA with a K166Q
HA mutation. For each sera sample, we completed three independent HAI assays. Shown are samples that had at
least a twofold reduction in HAI titer using the mutant virus in three independent experiments.

Table 11

Table S3. Characterization of K166 HA-specific sera
HAI titers
Sample ID

YOB

40–49
40–44
40–16
70–52
70–36
70–84
70–86
70–23
70–19
80–48
80–10
80–26
80–74
80–30
80–34
80–56
90–01
90–24
90–12
90–13

1943
1948
1949
1971
1972
1973
1973
1975
1978
1983
1986
1986
1986
1987
1987
1988
1990
1991
1992
1992

In vitro neutralization titers

A/CAL/07/09-WT HA A/CHOP/1/2013 A/CAL/07/09-WT HA

A/CAL/07/09-K166Q HA

<10
30
<10
<10
10
<10
20
<10
<10
30
160
80
40
10
160
<10
10
20
60
80

12
95
20
28
95
57
67
20
10
80
1,810
160
113
113
538
34
80
95
226
320

20
160
80
40
120
40
60
80
30
320
160
80
40
20
160
20
40
60
160
80

24
453
160
190
381
160
190
226
95
1,076
761
113
135
67
381
17
48
34
190
190

We further characterized several sera samples that had immunodominant K166 HA-specific Abs (light gray:
K166 HA-specific sera from individuals born before 1985; darker gray: sera from individuals born after 1985). HAI
assays were completed using viruses with the A/California/07/2009 HA-WT and a primary pH1N1 virus isolated
from the Children’s Hospital of Philadelphia (CHOP) in 2013. Additional in vitro neutralization assays were
Table
11. Characterization
of K166
sera.of two independent experiments.
completed
using the reverse-genetics
derivedHA-specific
viruses. Data arehuman
representative
For each neutralization assay, each sample was titered four times, and geometric mean of these quadruplicate
samples is reported.

We further characterized several sera samples that had immunodominant K166 HAspecific Abs (light gray: K166 HA-specific sera from individuals born before 1985;

darker gray: sera from individuals born after 1985). HAI assays were completed using
viruses with A/California/07/2009 HA-WT and a primary pH1N1 virus isolated from the
Children’s Hospital of Philadelphia (CHOP) in 2013 (A/CHOP/1/2013) that contains
Q166. Additionally, in vitro neutralization assays were completed using the reversegenetics derived viruses. Data are representative of two independent experiments. For
each neutralization assay, each sample was titered four times, and the geometric mean of
these quadruplicate samples is reported.
Linderman et al. www.pnas.org/cgi/content/short/1409171111

6 of
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Table 12
Table S4. Vaccination elicits K166 HA-specific responses
Visit 1 (prevaccine)
ID

YOB

USSR/77

Visit 2 (postvaccine)

Chile/83

Texas/91

NC/99

SI/06

CAL/09

CAL/09-K166Q

CAL/09-WT

CAL/09-K166Q

240
160
40
80
60

160
120
60
40
30

320
240
30
80
80

60
120
10
40
40

80
240
60
60
80

120
<10
<10
10
<10

20
<10
<10
<10
<10

160
40
120
160
60

20
10
<10
10
20

80
10
40
80
80
<10
40
80
40
30
40
<10

80
<10
<10
80
<10
<10
<10
40
<10
30
<10
<10

120
<10
30
80
320
<10
30
160
<10
60
240
30

<10
10
80
<10
240
<10
80
80
<10
<10
80
<10

<10
40
120
<10
320
<10
120
80
<10
<10
120
<10

60
10
<10
<10
<10
<10
10
<10
<10
<10
<10
<10

60
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10

80
40
80
120
240
80
20
20
240
240
160
60

60
40
80
80
320
80
20
20
320
240
160
60

K166-specific donors
1
1979
6
1966
7
1966
13
1982
21
1958
Other donors
2
1976
5
1949
8
1961
9
1977
10
1983
15
1961
17
1956
19
1961
20
1945
22
1956
23
1975
24
1968

HAI assays were completed using sera isolated from healthy donors before and after vaccination with the monovalent pH1N1 virus in
2009. Postvaccination sera were collected 30 d after vaccination. HAI assays using postvaccine sera were completed three independent
times and assays using prevaccine sera were completed two independent times. Red indicates HAI titers equal to or less than 10 and
yellow indicates HAI titers greater than 10.

Table 12. Vaccination elicits K166 HA-specific Ab responses in humans.

HAI assays were completed using sera isolated from healthy donors before and after
vaccination with the monovalent pH1N1 virus in 2009. Post-vaccine sera were collected
30 d after vaccination. HAI assays using post-vaccination sera were completed three
independent times and assays using pre-vaccine sera were completed two independent
times. Red indicates HAI titers equal to or less than 10 and yellow indicates HAI titers
greater than 10.
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Table 13
Table S5. Sera from ferrets sequentially infected with sH1N1 viruses and pH1N1
Day 14
First infection

Second infection

USSR/90/77

A/California/07/09

A/Chile/01/83

A/California/07/09

A/Singapore/06/86

A/California/07/09

A/California/07/09

A/California/07/09

None

A/California/07/09

Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group
Group

1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
4
4
4
5
5
5

Day 84

Day 98 (14 d after
second infection)

Animal no.

WT

K166Q

WT

K166Q

WT

K166Q

7982
7983
7984
7985
7991
7993
7994
7995
7987
7988
7989
7990
7996
7997
8000
8001
1487
1488
1481
1504
8002
8009
8010
8012
8013
8014
8015
1486
1497
1492

<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
400
800
800
ND
ND
ND

<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
400
800
800
ND
ND
ND

<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
80
<10
<10
60
<10
<10
<10
<10
200
400
300
ND
ND
ND

<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
<10
120
<10
<10
80
<10
<10
<10
<10
200
400
200
ND
ND
ND

800
800
300
800
2,400
800
600
400
1,200
800
800
1,600
1,200
240
600
800
6,400
3,200
2,400
4,800
1,600
1,600
4,800
1,600
160
2,400
2,400
1,600
1,600
1,200

800
800
300
600
2,400
1,200
600
600
800
400
400
1,600
400
160
800
800
6,400
3,200
3,200
6,400
2,400
2,400
6,400
2,400
160
2,400
1,600
2,400
1,600
1,600

Ferrets were infected with a sH1N1 virus and bled 14 and 84 d later. Animals were then infected with a pH1N1 strain and bled 14 d later (98 d post first

infection). Sera were isolated and HAI assays were completed using WT and K166Q-HA pH1N1 viruses. Data are representative of three independent HAI
Table
13. Analyses of sera from ferrets sequentially infected with sH1N1 viruses and
assays. The three ferrets with K166 HA-specific Ab responses had >twofold changes in HAI titer using the K166Q virus in three independent experiments. Red
highlights twofold or greater reductions in HAI titer using K166Q-HA pH1N1 virus compared to WT-HA pH1N1 virus. ND, not determined.

pH1N1.
Ferrets were infected with a sH1N1 virus and bled 14 d and 84 d later. Animals were then
infected with a pH1N1 strain and bled 14 d after second infection (98 d post-first
infection). Sera were isolated and HAI assays were completed using WT and K166Q-HA
pH1N1 viruses. Data are representative of three independent HAI assays. The three
ferrets with K166 HA-specific Ab responses had at least a twofold reduction in HAI titer
against the K166Q mutant virus in three independent experiments. Red highlights
twofold or greater reductions in HAI titer using K166Q-HA pH1N1 virus compared to
WT-HA pH1N1 virus. ND, not determined.
Linderman et al. www.pnas.org/cgi/content/short/1409171111

8 of 8
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CHAPTER 5 – OVERALL CONCLUSIONS, DISCUSSION,
AND FUTURE DIRECTIONS

In our studies, we explored multiple aspects of the current influenza virus
surveillance and vaccine strain selection process. First, we found that recent H3N2
viruses rapidly acquire mutations when propagated in cell culture. Mutations arose in
both HA and NA after a single passage of clinical isolates in MDCK cells. We identified
NA mutations that resulted in NA-dependent sialic acid binding and an HA mutation that
increased receptor binding avidity. Both HA and NA mutations increased viral infectivity
and hemagglutination titers. We found that these mutations altered HAI assays that are
commonly used for the antigenic characterization of influenza virus isolates. Second, we
determined that a single mutation in HA antigenic site B of H3N2 viruses contributed to
the influenza vaccine mismatch during the 2014-2015 season. Inclusion of the F159S HA
mutation in HA antigenic site B drastically decreased the ability of ferret, sheep, and
human Abs to bind and neutralize the virus. Because a single mutation in an antigenic site
can result in a vaccine mismatch, accurate surveillance and correct antigenic
characterization of circulating strains is vital in producing an effective influenza vaccine
each year. Third, we examined how different sH1N1 pre-exposure histories can result in
unique anti-pH1N1 Ab repertoires. Over 40% of middle-aged adult blood donors (born
1965-1979) were found to possess Abs specific for an HA epitope that recently acquired
a mutation (K166Q). Vaccinated middle-aged adults also possessed Abs with this
specificity, which left them more susceptible to influenza infection with pH1N1 strains
containing Q166. Sera isolated from ferrets recovering from a primary pH1N1 infection
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did not possess Abs that recognized this epitope, but sera from ferrets sequentially
infected with a 1983 sH1N1 virus and then challenged with the 2009 pH1N1 virus did
possess Abs that were sensitive to the K166Q mutation. Therefore, Abs in the sera of
ferrets recovering from primary influenza virus infections do not have the same
specificity of Abs isolated from humans who have been sequentially exposed to different
influenza virus strains.

Mutations acquired during viral propagation complicate influenza surveillance
Cell culture-derived mutations have been shown to alter HA stability (Nakowitsch
et al., 2014; Nakowitsch et al., 2011), reduce immunogenicity (Chen et al., 2010b), and
affect NA activity (Wang et al., 2013). Over the past two decades, H3N2 influenza
viruses have seen a steady decline in their receptor binding avidity (Gulati et al., 2013;
Lin et al., 2012). This has led to poor growth during cell culture propagation because the
viruses are unable to bind to their sialic acid receptors and infect cells for replication. We
passaged 10 clinical isolates from H3N2-infected children on MDCK cells, and observed
a high rate of mutations in both HA and NA. The P237L HA mutation increased receptor
binding avidity, possibly by stabilizing the HA trimer because HA residue 237 is located
at the trimer interface. The D151G and D151N NA mutations that arose were responsible
for NA-dependent binding of sialic acid, as has been seen previously (Lin et al., 2010;
Zhu et al., 2012). Both types of mutations are likely to effect antigenic analyses, as we
showed specifically with the P237L HA reverse genetics virus in an HAI assay, and as
other groups have shown with NA-dependent binding in HAI assays (Lin et al., 2010).
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This rapid acquisition of mutations in HA and NA during viral passage presents a
major problem for surveillance. For example, HA antigenic clade 3C.2a H3N2 viruses
acquire mutations when grown in MDCK cell culture (Skowronski et al., 2016). When
attempting to choose the correct viral strain to include in the influenza vaccine each year,
it is important to isolate and characterize the viruses that are actually circulating. If
isolates are acquiring mutations during propagation (before any analyses are completed),
the sequencing data and antigenic characteristics actually represent the cell cultureadapted H3N2 viruses, not the naturally occurring H3N2 viruses of interest.
Now that cell culture-derived mutations have been established as a major
complication to surveillance and vaccine selection, steps are being implemented to grow
and sequence influenza viruses more reliably. Previously, surveillance has been done
with a “passage-first” mentality where clinical isolates are immediately expanded in cell
culture to obtain a workable stock, then antigenically characterized, and finally
sequenced if an antigenic difference is detected (Krauss et al., 2012; Stöhr et al., 2012).
Now, the CDC is working on shifting to a “sequence-first” approach to surveillance,
where clinical isolates are immediately sequenced directly from the primary isolate
before any propagation or antigenic analyses are completed (Dormitzer et al., 2013). This
method eliminates the possibility that cell culture adaptive mutations will arise before
sequencing can be completed. The other main change in surveillance is the discovery that
using a different cell culture system can actually decrease the amount of mutations that
arise during propagation. Instead of using the classic MDCK cells for viral propagation,
using MDCK-SIAT1 cells for viral propagation allows recent H3N2 viruses to grow
without the need for adaptive mutations (Abdoli et al., 2016; Krauss et al., 2012; Oh et
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al., 2008). MDCK-SIAT1 cells are a form of MDCK cells that have been engineered to
express a higher concentration of α2,6-linked sialic acids on their surface (Matrosovich et
al., 2003), which serve as the receptor for human influenza viruses. With more receptor
present, even the H3N2 viruses with very low receptor binding avidity are able to infect
the cells and grow well. So by using a “sequence-first” approach and MDCK-SIAT1 cells
for viral propagation, the previous complications seen in H3N2 surveillance due to cell
culture-adaptive mutations should be avoided.

NA-dependent receptor binding is a recent observation in the influenza field
For as long as the influenza research field has existed, the central dogma is that
HA is responsible for binding and entry, and NA is responsible for release. However,
multiple groups have now begun to identify viruses that bind to sialic acid through NA
instead of HA (Lin et al., 2010; Zhu et al., 2012). The caveat here is that, so far, NAdependent binding has only been detected following propagation in cell culture. Similar
to what we found in Chapter 2, other groups have concluded that primary isolates do not
contain the D151G or D151N NA mutations responsible for the NA-binding phenotype
(Lee et al., 2013; Okomo-Adhiambo et al., 2010). The question now is whether a
continued reduction of HA receptor binding avidity in H3N2 viruses will result in the
need for NA-dependent sialic acid binding even in naturally circulating viruses. Lin and
colleagues demonstrated through reverse genetics that only a single mutation at NA
residue 151 is required for NA-dependent binding. They inserted the D151G or D151N
NA mutations and observed increased receptor binding via higher levels of NAdependent agglutination (Lin et al., 2010). With only a single mutation required for this
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NA-dependent binding phenotype, it seems possible that a circulating isolate with NAdependent binding could emerge. However, mutations at D151 decrease NA sialidase
activity and may hinder the virus without compensatory mutations (Zhu et al., 2012).
Overall, NA-dependent binding of sialic acid is a major shift in the dogma of the
influenza community. It is currently just a cell culture-derived phenomenon that has yet
to be observed in a primary isolate, but it can still have an impact on surveillance and
vaccine selection, which rely on the propagation of primary isolates in cell culture.

Reduced receptor binding avidity of H3N2 viruses presents difficulties in vaccine
manufacturing and production
Another complication presented by the poor growth of H3N2 viruses in cell
culture and eggs, is the effect it has on vaccine manufacturing and production. Although
MDCK-SIAT1 cells appear to be a good alternative to MDCK cells for cell culture
propagation, egg-based propagation still requires adaptive mutations for H3N2 viruses to
grow. And because almost all influenza vaccines are currently produced in eggs, this
limits the effectiveness of H3N2 vaccines. For example, the choice of the H3N2 vaccine
component for the 2015-2016 influenza season was heavily influenced by which clade of
H3N2 viruses could grow well in eggs. Although HA antigenic clade 3C.2a was
dominating circulation, a virus from HA antigenic clade 3C.3a was chosen as the vaccine
strain (Anonymous, 2015). This is because the HA Y159+T160 epitope present in HA
antigenic site B of Clade 3C.2a viruses cannot grow in eggs, consistent with our findings
that we were unable to rescue and grow the A/Texas/50/2012-F159Y+K160T mutant
virus in Chapter 3 without it acquiring mutations. When grown in eggs, these viruses
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quickly acquire mutations at HA residue 160, resulting in a loss of a glycosylation at
residue 158, thus drastically altering the antigenicity of HA antigenic site B in these
viruses (Chambers et al., 2015). Egg-adaptive mutations that emerge during vaccine
production are a common concern and have even been implicated as the reason for the
H3N2 vaccine mismatch during the 2012-2013 influenza season (Skowronski et al.,
2014). One way around this issue is to focus more on cell-based vaccine production.
Recent work shows that MDCK-SIAT1 cells can be successfully used to produce high
quality vaccines without mutations (Abdoli et al., 2016; Oh et al., 2008). Although this
would be a difficult shift for vaccine producers, it would likely result in a more reliable,
uniform, and effective influenza vaccine.

The immunodominance of HA antigenic site B in neutralizing Ab responses against
H3N2 influenza viruses and the possible role of glycosylation
Influenza viruses constantly accumulate mutations in Ab binding epitopes
scattered around the globular head of HA in order to escape prior immunity and continue
circulating. This process is termed antigenic drift and is responsible for the vaccine strain
updates that are required every few years for each influenza subtype. In Chapter 3, we
identified a mutation that emerged in H3N2 viruses during the 2014-2015 influenza
season and resulted in a vaccine mismatch. The mutation was located in HA antigenic
site B, and accounted for almost all of the antigenic distinction between the 2014-2015
vaccine strain and the newly emerged 2014-2015 viruses. HA antigenic site B has been
repeatedly implicated as an important site for antigenic drift mutations throughout the
evolution of H3N2 viruses (Koel et al., 2013; Popova et al., 2012). Although most of the
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previous work has been done utilizing antisera collected from previously naïve ferrets
infected for the first time with influenza, our study demonstrated that the majority of
human Ab responses against current H3N2 viruses are also directed against HA antigenic
site B.
So why is HA antigenic site B such an immunodominant epitope for Ab responses
against H3N2 viruses? The term immunodominant refers to the majority of the response
being focused on a specific epitope (Popova et al., 2012; Rajnavolgyi et al., 1997). One
hypothesis regarding the importance of HA antigenic site B is that this antigenic site is
one of the few sites on H3 viruses that are not glycosylated (Meyer and Wilke, 2015).
H3N2 viruses have continuously gained glycosylation sites in HA since being introduced
into humans in 1968 (Suzuki, 2011; Tate et al., 2011; Vigerust et al., 2007). The large Nlinked glycosylations attached to the HA surface present a high level of steric hindrance
to binding Abs (Pentiah et al., 2015; Tate et al., 2014). Only the HA surfaces left open
and exposed can act as Ab binding epitopes, thus focusing the Ab response to specific
epitopes over time as more glycosylation sites are added. This fits well with the
hypothesis we made in Chapter 4 regarding the sharp decline of K166 HA-specific H1N1
Ab responses in humans born after 1986. A new glycosylation site was added to sH1N1
viruses beginning in 1986 and it is predicted to act as an umbrella-like shield that covers
and hides the K166 HA-epitope from Ab binding. Multiple studies have already
implicated the addition of glycosylation sites in antigenic change and abrogation of Abs
that previously bound to HA (Tate et al., 2014). For example, inserting two or four
additional glycosylation sites into the 1968 H3N2 pandemic strain reduced neutralizing
Ab titers and increased immunopathology compared to the WT virus in previously naïve
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mice (Wanzeck et al., 2011). Therefore, it is likely that glycan shielding plays an
important role in limiting the antigenic sites available to anti-H3N2 Abs.
Other possible explanations of the HA antigenic site B immunodominant response
against H3N2 viruses include the location of site B directly at the top of the HA head and
its proximity to the receptor binding site. It is clear that future influenza virus
surveillance should monitor H3N2 viruses for the emergence of new mutations in HA
antigenic site B that could signal antigenic drift. This approach of closely monitoring HA
antigenic site B mutations can even be taken a step further. Multiple groups have recently
shown that growth of a historical influenza virus in vitro, in the presence of polyclonal
sera, will actually elicit escape mutations that recapitulate the antigenic drift that has
occurred in nature (DeDiego et al., 2016; Li et al., 2016). Passaging of the H3N2 virus
A/Victoria/361/2011 in the presence of polyclonal human antisera elicited mutations in
HA antigenic site B at residue 156, the exact residue that was mutated in antigenically
drifted H3N2 viruses of the 2012-2013 influenza season (DeDiego et al., 2016). Li and
colleagues also concluded that residues 153-156 in HA antigenic site B play a key role in
influenza antigenicity (Li et al., 2016). By growing the current H3N2 vaccine strain in the
presence of polyclonal human sera, we may be able to predict future mutations that will
arise in HA antigenic site B. This information could then be used to create antigenically
drifted vaccine strains. This work in association with recent observations of “backboosting,” where infection with an antigenically drifted H3N2 virus actually boosts Ab
titers even higher against previously seen strains (Fonville et al., 2014), may present a
new vaccination strategy: using escape mutations to generate artificially drifted influenza
strains, and then using a prime-boost vaccine regimen where the currently circulating
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strain is the first vaccination and the artificially drifted strain is the second vaccination.
This would in theory boost titers against the currently circulating strain even higher than
multiple vaccinations with just the current strain.
However, it is important to remember that antigenic sites other than HA antigenic
site B may be important for H3N2 antigenic drift as well. Similar to Ab responses elicited
against pH1N1 viruses, anti-H3N2 Ab responses may have different specificities in
different individuals due to unique pre-exposure histories. This topic will be discussed in
more detail later in this chapter.

The human Ab response against pH1N1 viruses is determined by pre-exposure
history to sH1N1 viruses
While the majority of human anti-H3N2 Ab responses are focused on a single
antigenic epitope, human anti-H1N1 Ab responses can be targeted to multiple antigenic
sites on the HA surface. The exact target site is determined by an individual’s preexposure history and the conserved epitopes shared between previous strains and the
currently infecting strain (Li et al., 2013b; Linderman et al., 2014). Additionally, more
antigenic sites are available on the surface of H1 viruses because there are less
glycosylation residues present (Zhang et al., 2013b). As discussed in the previous section,
H3 viruses are heavily glycosylated (Suzuki, 2011; Tate et al., 2011; Vigerust et al.,
2007) and HA antigenic site B may be the only epitope accessible for Ab binding (Meyer
and Wilke, 2015; Pentiah et al., 2015; Tate et al., 2014). Recent H1 viruses, on the other
hand, have very few glycosylation sites. In fact, the pH1N1 viruses that emerged in 2009
contained only a single potential glycosylation site on the HA head (Job et al., 2013).
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Studies have demonstrated that the addition of more glycosylation sites into the pH1N1
head results in resistance to neutralizing Abs (Job et al., 2013) and that different
glycosylation sites can alter antigenicity of H1N1 viruses (Sun et al., 2013). However,
there are currently very few potential glycosylation sites in circulating pH1N1 strains,
resulting in a wide array of exposed Ab binding epitopes across the HA head.
The data presented in Chapter 4 demonstrates that different sH1N1 pre-exposure
histories elicit unique Ab responses against distinct HA epitopes of the pH1N1 virus.
Different aged individuals within the human population have unique Ab specificities (Li
et al., 2013b; Linderman et al., 2014). Individuals are infected early in life by H1N1
viruses that circulate during their respective childhoods. When they are challenged later
in life with an antigenically distinct pH1N1 virus, there are a limited number of
conserved epitopes shared between the current pH1N1 virus and the sH1N1 virus seen
early in life. Memory B cells specific for conserved epitopes are recalled and produce the
majority of the Abs in the secondary response. Humans born during different decades
have been exposed to different sH1N1 viruses early in life, thus explaining why different
age groups elicit Ab responses with different specificities against pH1N1 viruses.

H1N1 pre-exposure history elicits a unique Ab response in middle-aged adults
against pH1N1 virus that correlates with higher susceptibility to infection
Influenza surveillance and vaccine strain selection have always relied heavily on
the use of antisera collected from previously naïve ferrets infected only one time with
influenza virus. Previous work from our lab has demonstrated that Abs elicited in
previously naïve ferrets infected with the 2009 pH1N1 virus a single time do not have the
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same specificity as anti-pH1N1 Abs elicited in young adults (born 1983-1996) (Li et al.,
2013b). The data presented in Chapter 4 demonstrates that the use of sera collected from
previously naïve ferrets infected with a single influenza virus is also leading to the
antigenic mischaracterization of newly emerged HA mutations. Specifically, we found
that a K166Q HA mutation that became fixed in pH1N1 viruses during the 2013-2014
influenza season abrogates the binding of Abs in the sera of a large portion of middleaged adults (born 1965-1979). It was hypothesized that this Ab specificity for the HA
epitope including residue K166 is present in middle-aged adults because the K166 HAepitope is conserved between the pH1N1 virus of 2009 and the sH1N1 strains that
circulated during their childhoods (the 1970s and early 1980s). To test this hypothesis,
we sequentially infected ferrets with a sH1N1 virus from 1983 and then the 2009 pH1N1
virus. We found that these animals mounted Abs that recognized the HA epitope
involving residue K166 that is conserved between the 1983 sH1N1 virus and the 2009
pH1N1 virus. The functional consequence of these K166 HA-specific Abs was also
determined using passive transfer experiments in mice where mAbs specific for the
epitope involving K166 did not protect mice against viruses possessing Q166.
This conclusion that Abs specific for the K166 HA-eptitope make the individual
more susceptible to severe infection correlates well with the observation that middle-aged
adults experienced a drastically increased burden of severe influenza infections during
the 2013-2014 season. According to WHO reports, middle-aged individuals (defined by
the WHO as 18-64 years old) experienced 61.2% of influenza-related hospitalizations and
62% of influenza-related deaths during the 2013-2014 influenza season (Arriola et al.,
2014). Typically, those values are between 20-35% for an individual influenza season.
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The majority of severe influenza infections usually affect those with weaker immune
systems: the very young (0-4 years old) and the elderly (>65 years old). We recently
completed additional experiments where we defined the specificity of sera collected from
323 individuals prior to the 2013-2014 influenza. We found that individuals that
possessed Abs focused on the K166 HA-epitope were more prone to pH1N1 infection
during the 2013-2014 influenza season (Petrie et al., under review).

Identification of the unique anti-pH1N1 Ab responses in other age groups
Our group has now identified the specificities of anti-pH1N1 Abs that are
common among individuals in two separate age groups. As explained above, the unique
pre-exposure history of individuals in each age group to different sH1N1 viruses early in
life led to different anti-pH1N1 Ab responses. Young adults (born 1983-1996) possess an
Ab response targeted to the HA epitope involving residue K133 (Li et al., 2013b).
Middle-aged adults (born 1965-1979) possess an Ab response targeted against the K166
HA-epitope (Huang et al., 2015; Linderman et al., 2014). The epitope involving K133
was present in sH1N1 viruses circulating between 1983-1996 and the epitope involving
K166 was present in sH1N1 viruses circulating prior to 1983.
It is possible that there are different Ab specificities that are common among
individuals in other age groups as well. For example, it would be very interesting to
investigate the anti-pH1N1 Ab specificity of children. School-aged children have been
implicated as the main population responsible for transmission during annual influenza
circulation (Petrie et al., 2013; Viboud et al., 2004). Being the main population for
transmission would exhibit a large immune pressure that may have already forced the
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virus to adapt and mutate to avoid the unique Ab specificity present in young children.
However, none of the mutations that have emerged in pH1N1 viruses since 2009 appear
to have an effect on the Ab binding of sera isolated from influenza-exposed children
(unpublished data from our lab). Likewise, although the Ab specificity of young adults is
against the epitope involving HA residue K133, this epitope has not yet acquired a
mutation in circulating pH1N1 viruses. There could be many forces at play that we do not
yet understand on how influenza viruses continuously circulate. Different age groups may
allow for transmission in different geographical locations, or each age group may be
partially responsible for circulation. Nonetheless, the population that controls the
majority of transmission and circulation should have the largest immune pressure on
forcing antigenic drift mutations in the pH1N1 HA gene segment.

Do these unique secondary Ab responses represent original antigenic sin?
Pre-exposure history has been shown here to elicit unique Ab responses against
pH1N1 influenza virus in different age groups of the human population. The specificity
of these unique Ab responses is determined by the HA epitopes conserved between the
sH1N1 strains these individuals were infected with early in life and the pH1N1 virus they
are being challenged with now. Whenever a secondary Ab response is altered and
characterized depending on previous infections, it is necessary to establish whether
original antigenic sin (OAS) is playing a role. In general, OAS describes the observation
that even when infected with a novel influenza strain, humans will produce Abs against
previously encountered strains at the expense of mounting effective responses against the
current novel strain (Davenport et al., 1953; Francis, 1960). In that sense, our
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observations of different pre-exposure histories leading to unique Ab repertoires would
not fall under the category of OAS for one major reason: there is no so-called “sin”
observed in our studies. Take the middle-aged adult age group with Abs specific for the
K166 HA-epitope for example. Although these individuals preferentially mount an Ab
response that is specific for an epitope present in the sH1N1 strains they saw early in life,
they still mount sufficiently high responses against the A/California/07/2009 pH1N1
strain. If this were an example of OAS, the Ab response would be high against past
sH1N1 strains at the expense of high titers against the currently infecting strain. As long
as the K166 HA-epitope is intact, the Ab response against the current strain is protective.
It’s only when HA residue 166 is mutated that this K166 HA-specific Ab response is
deleterious. It remains to be seen whether viruses possessing Q166 recall Ab responses
that target the K166 HA-epitope in individuals with sH1N1 pre-exposures from the early
1980s.
Another question along the lines of OAS to consider is whether an individual’s
first influenza exposure is really the most important in shaping lifelong immunity. An
alternate way to look at this is whether these unique Ab responses we have discovered in
different age groups are actually fully dependent on the epitopes conserved between the
current pH1N1 strain and the very first sH1N1 strain with which they were infected. So
not just “strains they saw early in life,” but rather “their very first sH1N1 infection.” This
could help explain why only 42% of our middle-aged adult sera possessed Abs sensitive
to the K166Q mutation. The individuals without this Ab specificity for the K166 HAepitope may have been first infected with an A/USSR/90/1977-like virus which does not
have the K166 HA-epitope intact. Even if they were later infected with a sH1N1 strain
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with an intact K166 HA-epitope (like A/Chile/1/1983), they would still not mount an Ab
response specific for the K166 HA-epitope. Only those infected for the first time with a
sH1N1 virus with the K166 HA-epitope intact would produce this unique specificity later
in life. Previous studies have suggested that an individual’s first influenza exposure
confers an antigenic seniority to their response, which is continually boosted with
repeated sequential infections (Kucharski et al., 2015; Lessler et al., 2012; Miller et al.,
2013). Overall, the unique Ab responses mounted against pH1N1 viruses in different age
groups generally do not represent true OAS. Although the specificity of the response is
dictated by sH1N1 strains seen early in life, the response is still sufficient enough to
protect against the current pH1N1 strain. Only when a mutation arises in that specific
epitope does sin truly occur in that the response is highly effective against past strains,
but low in effectiveness against the current strain.

Does pre-exposure history have as much of an impact on shaping the anti-H3N2
influenza response?
Our data suggests that pre-exposure to different sH1N1 strains can affect the Ab
specificity against pH1N1 infections later in life. This presents a new factor that must be
taken into account during vaccine selection and antigenic characterization of newly
emerged mutations. However, it will also be important to determine whether preexposure history shapes unique Ab responses against subsequent H3N2 influenza
infections as well. One major difference between H1N1 and H3N2 viruses is the level of
antigenic distinction between the strains seen early in life and those currently circulating.
Although sH1N1 and pH1N1 viruses are classified as the same subtype of influenza, they
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are thought of as two entirely different pandemics because pH1N1 viruses emerged after
obtaining a genetically divergent HA gene segment from a classical swine lineage
(Garten et al., 2009). Approximately 20-30% of the amino acid residues in HA are
different between sH1N1 viruses and pH1N1 viruses (Li et al., 2012). This substantial
difference, especially in the variant globular head domain, does not leave many
conserved epitopes shared between sH1N1 and pH1N1 viruses. A limited availability of
conserved epitopes may be required for the focusing of an immunodominant response on
a specific HA epitope, similar to what we found in the middle-aged adult sera regarding
the K166 HA-epitope. On the other hand, H3N2 viruses of the 1960s and 1970s are at
most 8-12% different in their HA sequences compared to H3N2 viruses of today
(Bedford et al., 2010; Broberg et al., 2015; Smith et al., 2004). This results in many more
conserved epitopes between H3N2 strains, which may limit the ability of the secondary
Ab response to be focused on a single shared epitope.
H3N2 viruses have been circulating constantly in humans since 1968. In that time
they have acquired multiple mutations in each of the five antigenic sites of H3N2 HA
(Smith et al., 2004). Derek Smith’s group has completed elegant work to take an in-depth
look at the evolution of H3N2 viruses and the requisition of antigenic drift mutations.
Through the use of previously naïve ferret antisera, they identified a set of several
residues in HA antigenic site B that are responsible for the majority of antigenic drift in
H3N2 viruses over the past 50 years (Koel et al., 2013). However, many other mutations
have become fixed in the other H3 antigenic sites as well during that time. Our
hypothesis is that mutations are elicited in these other sites in order to escape other Ab
responses mounted in individuals with unique H3N2 pre-exposure histories. So similar to
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the H1N1 pre-exposure history observations, individuals with different H3N2 preexposure histories might possess anti-H3N2 Abs against different epitopes of HA; and
H3N2 viruses might acquire mutations in all these epitopes in order to escape population
immunity and continue circulating. So although Derek Smith and his colleagues have
carried out great investigations into H3N2 antigenic drift, their answers are potentially
skewed and limited by their use of only sera collected from previously naïve ferrets to
antigenically characterize historic H3N2 viral isolates. Pre-exposure history in the human
population could have shaped unique Ab responses to epitopes other than HA antigenic
site B. This hypothesis is also supported by our human sera data from Chapter 3, where
although the majority of our human sera cohort possessed Abs against HA antigenic site
B, about 12.5% had high titer Ab responses targeted elsewhere on HA.
We are currently conducting studies to determine the importance of H3N2 preexposure history on the Ab response against gradually drifted H3N2 viruses, and how it
compares to what we observed with H1N1 pre-exposure histories. As we have shown
previously with H1N1 infections, ferrets sequentially infected with antigenically distinct
influenza strains will recapitulate the unique Ab responses observed in humans (Li et al.,
2013b; Linderman et al., 2014). For our H3N2 study, ferrets were sequentially infected
with antigenically distinct H3N2 viruses in order to determine if Ab specificities would
be shifted to epitopes conserved between the two strains. Preliminary data indicates a
possible shift in the Ab binding epitope between different ferret groups, but more data
and experiments are needed before making final conclusions regarding H3N2 preexposure history and the impact it has on shaping Ab responses.
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Concluding Remarks
Overall, my work has investigated multiple factors that complicate viral
surveillance and selection of effective vaccine strains for the annual influenza vaccine.
Poorly growing H3N2 isolates acquire mutations quickly during cell culture propagation
and hinder antigenic characterization, vaccine selection, and even vaccine production.
Unique Ab repertoires elicited by different pre-exposure histories are not represented
through the use of sera collected from previously naïve ferrets infected with influenza for
the first time in current surveillance techniques. This leads to mischaracterization of the
antigenic importance of newly emerging HA mutations. And as we demonstrated with the
single HA antigenic site B mutation in H3N2 viruses during the 2014-2015 influenza
season, even single mutations can lead to antigenic drift and complete vaccine
mismatches.
Even though the future of influenza vaccination may be destined to include more
universal approaches, such as recombinant proteins, peptide antigens, and DNA-based
vaccines, it is still important to continue improving our current vaccination techniques.
Steps are already being taken to improve viral surveillance. The adoption of a “sequence
first” strategy will ensure that sequencing data matches that of circulating strains, without
the danger of cell culture-adaptive mutations. The utilization of MDCK-SIAT1 cells for
propagation will decrease the number of cell culture-adaptive mutations and allow recent
H3N2 viruses to grow well enough for true antigenic characterization and vaccine
selection. However, more steps need to be taken. The current egg-based vaccine
manufacturing process results in egg-adaptive mutations during production, possible
vaccine mismatches, and a limit on which viruses can be selected for inclusion in the
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influenza vaccine. Adoption of a cell culture-based vaccine manufacturing process could
reduce the level of variation in vaccine stocks and also allow for some viral clades with
low fitness to be included when relevant.
Another vital factor in improving the influenza vaccine will be making sure that
antigenic characterizations of newly emerged mutations are correct. As we have
demonstrated multiple times, sera collected from previously naïve ferrets infected with
influenza a single time do not detect all the antigenically important mutations that
emerge. Different human age groups have different Ab repertoires against the same virus
due to unique pre-exposure histories. This does not call for personalized vaccine strains
based on age; that would be too difficult and too expensive to be feasible. However, what
is required is a more stringent detection system that will accurately characterize the
antigenic importance of every mutation. One approach that could improve antigenic
characterization of newly emerged mutations would be the use of sequentially infected
ferret antisera. As we have demonstrated multiple times (Li et al., 2013b; Linderman et
al., 2014), ferrets infected sequentially with the same strains as humans are able to
recapitulate the immunodominant specificities observed in human Ab responses. Using a
set of differentially pre-exposed ferret groups, where each group is primed with a
different historic influenza virus and then re-challenged with the same current strain,
would hopefully allow us to represent all the unique Ab repertoires present in the human
population.
An alternative approach would be to simply use human antisera raised against
influenza virus. Collecting antisera from different aged humans and testing samples
individually could determine the antigenic effect of a newly emerged mutation on the
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entire spectrum of unique human Ab responses against the pH1N1 virus. In fact, based
upon the work and the conclusions presented above, the WHO has recently (within the
last month) changed the way they conduct viral surveillance and will now use human
antisera to determine antigenic change moving forward (Anonymous, 2016b).
Additionally, based upon the results they obtained using human antisera instead of
antisera from previously naïve ferrets, the WHO has elected to update the pH1N1 vaccine
strain for the first time since 2009 (Anonymous, 2016b). Using human antisera for
surveillance and vaccine strain selection moving forward will help ensure that the vaccine
strains are updated to more effective strains that better protect humans of all ages.
Annual vaccination against influenza virus is an important tool in fighting off a
disease that causes millions of infections and thousands of deaths in the United States
each year (Kostova et al., 2013; Reed et al., 2015). It is vital that the best strains are
chosen each year in order to get maximum vaccine effectiveness. Sometimes, vaccine
mismatches cannot be avoided due to the quick emergence of antigenically drifted
viruses. However, the continued use of sera collected from previously naïve ferrets
following a single influenza infection and MDCK-based cell culture propagation has
been putting the field at a disadvantage by not correctly characterizing the antigenic
importance of new HA mutations. Implementation of a “sequence-first” surveillance
program, an MDCK-SIAT1 cell culture system for primary isolates and vaccine
production, and the use of clinical human antisera for antigenic characterization of new
mutations are the next steps towards improving the annual influenza vaccine.
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